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Hepatocellular carcinoma (HCC) represents the second most common cause of 
cancer-related death worldwide, not least due to late diagnosis and insufficient 
systemic treatment options. Since HCC is linked to inflammation, one aim of this 
study was to characterise inflammatory events in early hepatocarcinogenesis. The 
data revealed a dramatic monocyte recruitment and altered lipid composition upon 
treatment with the carcinogen diethylnitrosamine (DEN), which is one of the most 
frequently used agents in mouse models inducing HCC. Further aims were to 
decipher actions of the mRNA-binding protein tristetraprolin (TTP, ZFP36) and of the 
long non-coding RNA nuclear paraspeckle assembly transcript 1 (NEAT1) in liver 
cancer. In human gene expression data sets comparing HCC to normal liver tissue, 
TTP was downregulated, whereas NEAT1 was upregulated. The experimental data 
suggest that hepatocytic Ttp promotes tumour formation, but that TTP inhibits tumour 
progression, i.e. migration, proliferation, and oncogene expression in human 
hepatoma cells. Chemoresistance induced NEAT1 and the formation of paraspeckles 
and transcripts encoding paraspeckle proteins are strongly predictive for a poor 
prognosis in human HCC. Taken together, this work provides evidence for TTP, 





Das Hepatozelluläre Karzinom (HCC) ist weltweit die zweithäufigste Ursache für 
krebsbedingten Tod, auch aufgrund einer späten Diagnose und unzureichender 
systemischer Behandlungsmöglichkeiten. Da Entzündung im HCC eine wichtige 
Rolle spielt, war ein Ziel dieser Studie, entzündliche Vorgänge in der frühen 
Hepatokarzinogenese zu charakterisieren. Die Daten zeigten eine starke 
Monozytenrekrutierung und veränderte Lipidzusammensetzung bei Behandlung mit 
dem Karzinogen Diethylnitrosamin (DEN), einem der am häufigsten verwendeten 
Karzionogenen in Mausmodellen, die HCC induzieren. Weitere Ziele waren die 
Aufklärung der Effekte des mRNA-bindenden Proteins Tristetraprolin (TTP, ZFP36) 
und der langen nicht-kodierenden RNA nuclear paraspeckle assembly transcript 1  
(NEAT1) bei Leberkrebs. In menschlichen Genexpressionsdatensätzen, die HCC mit 
normalem Lebergewebe vergleichen, wurde TTP herunterreguliert und NEAT1 
hochreguliert. Die experimentellen Daten legen nahe, dass hepatozytisches Ttp die 
Tumorbildung fördert, wohingegen TTP die Tumorprogression, d. h. Migration, 
Proliferation und Onkogenexpression, in humanen Hepatomzellen hemmt. Die 
Chemoresistenz-induzierte Expression von NEAT1, Paraspeckles und Transkripten, 
die für Paraspeckle-Proteine kodieren, sind für eine schlechte Prognose beim 
menschlichen HCC stark prädiktiv. Zusammengefasst liefert diese Arbeit Hinweise 
darauf, dass TTP, NEAT1 und Paraspeckles neue interessante Angriffspunkte für 






1.1 Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the predominant form of liver cancer and the 
second most common cause of cancer-related death worldwide (Figure 1; Bruix et 
al., 2015; Tang et al., 2017). Interestingly, more men than women are affected by 
HCC (Tang et al., 2017), which may be caused by an elevation of hepatic 
inflammatory events in men (Naugler et al., 2007). As a very heterogeneous and 
complex tumour, HCC is characterised by multiple genetic aberrations (Umeda et al., 
2017). The majority of patients are at initial diagnosis in later stages according to the 
Barcelona Clinic Liver Cancer (BCLC) classification (Wörns et al., 2009). This late 
diagnosis is one of the reasons why chemoresistance, which is linked to poor 
prognosis, is abundant in HCC and results in poor response rates to systemic drug 
treatment (Cheng et al., 2016; Jiao and Nan, 2012; Wörns et al., 2009; Yau et al., 
2008). 
 




1.1.1 Inflammation in hepatocarcinogenesis 
Many factors, such as infection with hepatitis B virus (HBV) or hepatitis C virus 
(HCV), carcinogens, diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), 
alcohol abuse, and cirrhosis induce liver injury. If untreated, these injuries further 
transform to chronic liver damage, which contributes to hepatic chronic inflammation. 
In order to restore liver function, compensatory proliferation occurs (Sun and Karin, 
2013). However, excessive compensatory proliferation can induce severe 
pathological changes including fibrosis, cirrhosis, and hepatocarcinogenesis (Sun 
and Karin, 2013). In addition, it is assumed that chronic inflammation promotes 
tumour progression (Balkwill and Mantovani, 2001; Nakamoto et al., 1998). 
1.1.2 Obesity in hepatocarcinogenesis 
Obesity seems to be one important risk factor for the development of HCC (Marengo 
2016). In obesity, adipocytes begin to swell due to an overload with triglycerides 
(TG). Eventually, they are stressed and can dedifferentiate, which results in the 
release of free fatty acids from TG by lipolysis and the reduced expression of 
adiponectin (Zimmermann et al., 2009; Larter et al., 2010). This subsequent lipid 
accumulation in the adipose tissue supports the development of insulin resistance. 
The mix of hyperinsulinemia and hyperglycemia further promotes hepatic synthesis of 
fatty acids and contribute to even higher hepatic TG levels (Reeves et al., 2016). In 
addition, the accumulation of free fatty acids in the liver may induce inflammation by 
increasing the levels of several cytokines such as tumour necrosis factor alpha (TNF-
a) (Arkan et al., 2005). Therefore, obesity causes insulin resistance mediated 
prolonged cell survival on the one hand and fatty acid mediated continuous 
generation of cytokines and reactive oxygen species (ROS) inside the liver on the 
other hand. These changes are likely to contribute to or even to promote 
hepatocarcinogenesis (Reeves et al., 2016). 
1.1.3 Chemical hepatocarcinogenesis  
Carcinogenesis may be induced by chemical compounds found in everday products. 
The N-nitroso compound diethylnitrosamine (DEN) for instance can be found in beer 
and whiskey, balloons and condoms, tobacco smoke, meat, salted fish, and latex 
gloves (Altkofer et al., 2005; Feng et al., 2009; Rywotycki, 2007; Sen et al., 1980; 
Tricker et al., 1991; Zou et al., 1994). Although there is a lack of studies about the 
effect of DEN in human carcinogenesis, data suggest that DEN is at least correlated 
Introduction 
11 
with cancers of the gastrointestinal tract after oral absorption, e.g. gastric cancer 
(Jakszyn and Gonzalez, 2006). DEN induces tumour initiation via DNA adduct 
formation after long-term treatment in animals (Verna et al., 1996). In rats, DEN 
treatment causes liver injury after a medium-term (2-8 weeks) treatment, which may 
progress to fibrosis, cirrhosis, and finally metastasising liver tumours (Liu et al., 
2009). In mice, DEN-induced HCC is one of the most frequently used animal models 
to study liver cancer (Fausto and Campbell, 2010), and DEN has also been used to 
induce hepatic inflammation in mice (Naugler et al., 2007). 
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1.2 The mRNA binding protein tristetraprolin 
The fate of many proteins, some of which play an important role in inflammatory 
processes, is strongly regulated by post-transcriptional modifications (Feigerlová and 
Battaglia-Hsu, 2017). In addition, the post-transcriptional control of gene expression 
is a crucial factor for proper cell homeostasis (Cooper et al., 2009). The regulation of 
messenger RNAs (mRNAs) prevents incorrect synthesis of proteins that could 
eventually lead to the development of a disease (Cooper et al., 2009; Castello et al., 
2013). Different factors, such as mRNA-binding proteins (RBPs) are able to regulate 
the fate of mRNAs. RBPs may interact with distinct elements in the mRNA and are 
able to either stabilise or destabilise the mRNA (Iadevaia and Gerber, 2015). The 
deregulation of RBPs has been linked to different cancers including HCC (Gutschner 
et al., 2014; Jeng et al., 2008; Wang et al., 2016). 
RBPs usually contain one or several characteristic RNA-binding motifs (e.g. a zinc 
finger motif), which enables them to specifically interact with their target mRNA. In 
order to implement specific control by targeting at a subset of mRNAs, RBPs mainly 
interact with sequences located in the 3'-untranslated region (3'-UTR) of mRNAs 
(Iadevaia and Gerber, 2015; Imig et al., 2012). 
Tristetraprolin (TTP, gene name ZFP36), a 34 kDa member of the CCCH class of 
tandem zinc finger proteins, is expressed in a variety of tissues (Blackshear, 2002) 
and accelerates the decay of its target transcripts (Baou et al., 2011). This mRNA-
destabilising role could be specially observed in a Ttp-deficient mouse model, in 
which Tnf mRNA was significantly stabilised in macrophages, which led to a 
significant elevation in circulating Tnf and contributed to symptoms of a systemic 
inflammatory syndrome (Carballo et al., 1998). This syndrome includes erosive 
arthritis, conjunctivitis, dermatitis, medullary and extramedullary myeloid hyperplasia 
associated with cachexia, glomerular mesangial thickening, and high titers of anti-
DNA and antinuclear antibodies (Taylor et al., 1996). In addition, TTP expression is 
frequently repressed in human cancers, such as gastric, lung, breast, ovarian, and 
colon cancer (Hitti et al., 2016; Sanduja et al., 2012), and a loss of functional TTP 
was shown to modulate different tumourigenic phenotypes (Brennan et al., 2009). 
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1.3 The lncRNA nuclear paraspeckle assembly transcript 1 
and nuclear paraspeckles 
The range of ncRNAs is enormous and exceeds by far the number of protein-coding 
mRNAs (<2%) (Fatica and Bozzoni, 2014). A large proportion of these ncRNAs are 
longer than 200 nucleotides, which are often polyadenylated and defined as long 
ncRNAs (lncRNAs) (Rinn and Chang, 2012; Batista and Chang, 2013). These 
lncRNAs can be found in both the nucleus and the cytoplasm and are able to perform 
a broad range of tasks including post-transcriptional modification (Fatica and 
Bozzoni, 2014; Faghihi et al., 2008). 
The nuclear paraspeckle assembly transcript 1 (NEAT1) is located in nuclear 
paraspeckles, which can be found in the nucleus (Clemson et al., 2009; Mao et al., 
2011; Souquere et al., 2010). The two transcript variants of NEAT1, which have been 
described in the literature, are the short NEAT1_v1 (NEAT1ε, 3.7 kb in length) and 
the long NEAT1_v2 (NEAT1-202, NEAT1β, 23 kb in length) (Naganuma et al., 2012). 
Furthermore, Ensembl lists 201 and 203-205 as additional transcript variants (Figure 
2). The transcripts NEAT1_v1 and NEAT1_v2 play an important role in paraspeckle 
formation: While the biosynthesis of paraspeckles is mainly NEAT1_v2-dependent, 
both transcripts are vital for the integrity of paraspeckles (Naganuma et al., 2012). 
Despite NEAT1_v1/v2, proteins, such as paraspeckle component 1 (PSPC1), non-
POU domain containing octamer binding protein (NONO), and RNA-binding motif 
protein 14 (RBM14) are also paraspeckle components. Due to the lack of an altered 
phenotype in Neat1 knockout mice, the biological role of paraspeckles is, as yet, 
widely unknown (Nakagawa and Hirose, 2012). Still, paraspeckles were reported to 
inhibit DNA damage-induced cell death and therefore contribute to tumourigenesis 
(Gao et al., 2014). Different human malignancies including lung cancer, colorectal 
cancer, prostate cancer, breast cancer, and HCC showed an increased expression of 
NEAT1 (Yu et al., 2017). Additionally, a NEAT1-dependent enhancement of 





Figure 2: Size and location of NEAT1 transcript variants on the NEAT1 gene locus on 
chromosome 11 (schematic). Please note that the scheme is not drawn in scale. 
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1.4 Aim of the present work 
HCC is a heterogeneous and complex tumour, and many mechanisms regarding its 
formation and progression remain elusive. Although it has been shown that 
inflammatory processes as well as lipid accumulation contribute to 
hepatocarcinogenesis, very little is known about the composition of inflammatory 
cells and lipids in an HCC promoting environment. Genetic aberrations are important 
factors in hepatic tumour progression, but only little is known about the role of TTP 
and NEAT1-dependent paraspeckles in hepatic carcinogenesis and tumour 
progression.  
  
The following hypotheses were tested: 
  
1) DEN induces leukocyte recruitment to the liver and alters lipid metabolism 
2) TTP plays a role in hepatocarcinogenesis and tumour progression 
3) NEAT1 and paraspeckles are induced in HCC chemoresistance and serve as 
prognostic marker 
DEN-induced leukocyte recruitment and lipid composition 
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2.1 Abstract 
Diethylnitrosamine (DEN)-induced hepatocellular carcinoma (HCC) in mice is one of 
the most frequently used animal models in liver cancer studies. Although it is 
commonly accepted that the toxic agent DEN induces inflammation and tumour 
development, the effects of DEN treatment on the composition of immune cells and 
hepatic lipids are mostly unknown. We therefore performed a comprehensive flow 
cytometric and analytical study to characterise immune cell and lipid composition in 
the livers of a DEN short-term mouse model to enhance the understanding of the 
mechanisms involved in a developing liver neoplasia. 
Liver and body weight, serum transaminases, ROS, and caspase-3-like activity were 
analysed in nine-week-old male C57BL/6 mice, which were intraperitoneally injected 
with either 100 mg / kg body DEN in 0.9% NaCl or a sham-control and sacrificed 48 h 
after injection. Lipids and lipogenic genes were characterised via GC-MS, TLC, and 
qPCR. Leukocyte composition and chemokine expression was determined via flow 
cytometry and qPCR. 
The total amount of leukocytes as well as the number of myeloid dendritic cells, 
neutrophils, and monocytes was significantly elevated in the livers of DEN-treated 
animals. In contrast, the proportion of macrophages was significantly reduced. The 
hepatic mRNA expression of the chemokine (C-X-C Motif) Ligand 1 (Cxcl1) showed 
increased levels in DEN-treated animals. Both hepatic lipid composition and serum 
levels were significantly altered in DEN-treated animals compared to sham treated 
mice. The amount of hepatic triglycerides as well as of specific single fatty acids were 
increased in the DEN-treated animals. Serum triglyceride levels were lowered in 
these animals, while serum cholesterol levels were elevated. The expression of 
carnitine palmitoyltransferase 1 (Cpt1a) was increased, whereas stearoyl-CoA 
desaturase 1 (Scd1), Fatty acid binding protein 1 (Fabp1), and fatty acid synthase 
(Fasn) were downregulated in livers of DEN-treated mice.  
Taken together, this report is the first to show the impact of DEN treatment on hepatic 
leukocyte and lipid composition.  
DEN-induced leukocyte recruitment and lipid composition 
18 
2.2 Introduction 
The carcinogenic potential of N-nitroso compounds was first discovered in 1937 
when it was reported that dimethylnitrosamine might induce liver damage in men 
(Freund, 1937). The carcinogen diethylnitrosamine (DEN) can be found in different 
products, including balloons and condoms (Altkofer et al., 2005), beer and whiskey 
(Sen et al., 1980), tobacco smoke (Tricker et al., 1991), meat (Rywotycki, 2007), 
salted fish (Zou et al., 1994), and latex gloves (Feng et al., 2009). Although not toxic 
itself, DEN unfolds its carcinogenic potential after hydroxylation via the CYP system 
(Verna et al., 1996). Especially CYP2E1 seems to play an important role in this 
bioactivation (Kang et al., 2007). In 1964, the first study including rats (Magee and 
Lee, 1964) introduced DEN into animal experiments: Since then, it has been widely 
used in animal models. DEN induces – like other N-nitroso compounds – DNA adduct 
formation and tumour initiation after long-term treatment (Verna et al., 1996). In rats, 
DEN treatment induces non-specific liver injury after a short-term (2-8 weeks) 
treatment progressing to fibrosis, cirrhosis, and finally metastasising liver tumours 
(Liu et al., 2009). In mice, DEN-induced hepatocellular carcinoma (HCC) is among 
the most frequently used animal models in liver cancer studies (Fausto and 
Campbell, 2010). 
HCC, the predominant form of liver cancer, is the second most common cause of 
cancer-related death worldwide (Bruix et al., 2015; Tang et al., 2017). Since the 
1980s, the incidence of HCC has increased in North America and Northern Europe, 
where it is mainly caused by type 2 diabetes, obesity, and metabolic disorders (El-
Serag, 2012; Reeves et al., 2016). An accumulation of lipids caused by obesity has 
been linked to a poor prognosis with increased mortality in HCC (Reeves et al., 
2016). In addition, it has been shown that chronic inflammation is a major factor in 
the development of HCC (Sun and Karin, 2013) and may promote tumour 
progression (Balkwill and Mantovani, 2001; Nakamoto et al., 1998).  
It is well established that DEN induces inflammation as well as tumour development. 
However, the effects of DEN treatment on the composition of immune cells and 
hepatic lipids are rather ill characterised. We therefore undertook a comprehensive 
flow cytometric and analytical study to characterise immune cell composition, lipid 
classes, and fatty acids in the livers of a DEN short-term mouse model. Our findings 
DEN-induced leukocyte recruitment and lipid composition 
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contribute to the understanding of the mechanisms involved in the development of 
liver neoplasia. 
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2.3 Materials and Methods 
2.3.1 Animals 
All animal procedures were performed in accordance with the local animal welfare 
committee (37/2014). Mice were kept under controlled conditions regarding 
temperature, humidity, 12 h day/night rhythm, and food access ad libitum. 32 nine-
week-old male C57BL/6 mice were intraperitoneally injected with either 100 mg / kg 
body weight DEN in 0.9% NaCl (Sigma Aldrich, Taufkirchen, Germany) or a 0.9% 
NaCl solution as a sham-control. 48 hours after the injection, the mice were 
sacrificed. The livers of 20 of the 32 animals were checked for immune cell 
composition via flow cytometry. The livers of 12 of the 32 animals were checked for 
lipid classes and fatty acids. All of the animals were analysed regarding serum 
parameters, body and liver weight. 
 
2.3.2 Flow cytometry 
In general, flow cytometry analysis was performed according to Wang et al. (2011). 
For determination of leukocyte composition, the liver was cut into small pieces and 
incubated with 0.04% collagenase type IV in RPMI 1640 medium (both obtained from 
Sigma Aldrich) for 45 min at 37°C while shaking. Afterwards, the liver was pressed 
through a 100 µm cell strainer (Fisher Scientific, Schwerte, Germany) and 40 ml pre-
cooled 1xPBS was added. The suspension was centrifuged (5 min, 4°C, 500 g), 
supernatant was discarded and another 40 ml of 1xPBS were added. About 1 ml of 
the suspension was extracted for determination of CD45+ cells, and the rest was 
centrifuged again. After discarding the supernatant, 20 ml isotonic Percoll solution 
(33.75 ml Percoll, 3.75 ml 10xPBS, 62.5 ml PBS) were added and the suspension 
was centrifuged (12 min, room temperature, 700 g). The supernatant was discarded 
and 8 ml TAC buffer (17 mM Tris, 140 mM ammonium chloride) was added. After 20 
min inversion at room temperature, the suspension was filtered again through a 100 
µm cell strainer. After adding 1 ml FCS-EDTA solution (10 mM EDTA in 100 ml FCS) 
and centrifugation (10 min, 4°C, 500 g), the supernatant was discarded and the cells 
were resuspended in 200 µl MACS buffer (0.5% BSA and 2 mM EDTA in PBS). After 
adding CD45 microbeads (10 µl per 107 cells, Miltenyi, Bergisch Gladbach, 
Germany), the suspension was incubated for 15 min on ice. The cells were washed 
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with 5 ml 1xPBS and centrifuged (10 min, 4°C, 500 g), and the supernatant was 
discarded. The cells were resuspended in 500 µl MACS buffer and transferred to a 
pre-eluted MS column (attached to the magnet). After washing three times with 500 
µl MACS buffer, the column was removed from the magnet and 1 ml MACS buffer 
was added to collect the CD45+ cells. The cells were counted, diluted (500,000 / vial), 
and centrifuged (3 min, 4°C, 500 g). Cells were resuspended in flow cytometry buffer 
(FCB; PBS containing 2.5% (v/v) bovine calf serum and 0.05% (w/v) NaN3) and 
incubated with mouse BD Fc Block (BD Biosciences, Heidelberg, Germany), as 
recommended by the supplier. 0.5 µg of each antibody were added: APC rat anti-
mouse Ly6G Clone 1A8 (#560599), APC-R700 rat anti-mouse CD11b Clone  M1/70 
(#564985), BV421 rat anti-mouse Ly6C Clone AL-21 (#562727), BV510 mouse anti-
mouse NK 1.1 Clone  PK136 (#563096), PE hamster anti-mouse CD11c Clone  HL3 
(#55740, all from BD Biosciences), and FITC human anti-mouse F4/80 clone 
REA126 (#130-102-327 from Miltenyi). After incubation for 15 min on ice in the dark, 
the suspension was centrifuged (3 min, 4°C, 500 g), the supernatant was discarded, 
and the pellet was washed with 1 ml FCB followed by centrifugation. After discarding 
the supernatant, cells were resuspended in 300 µl FCB and 10 µl cell viability 
solution (BD Biosciences) were added to each sample 10 min before flow cytometric 
analysis. 
The same protocol was used for the determination of CD45+ cells, but minor changes 
were applied: 1 million cells of the total liver homogenate were analysed using 1 µg 
of the FITC mouse anti-mouse CD45.2 Clone 104 antibody (#561874, BD 
Biosciences) and 20 µl of the cell viability solution. 
The stained cells were examined on a BD LSRFortessa™ cell analyser (BD 
Biosciences), and results were analysed using the FACS Diva and the FACSuite 
software (BD Biosciences). For each antibody, the number of positive cells was 
normalised to the total number of cells. 
To determine the composition of the leukocytes, the following gating strategy was 
applied: FSClow debris and erythrocytes, and multiplets with a non-linear SSC-A/SSC-
H ratio were excluded. Viability was determined by 7-AAD staining. Viable cells (7-
AAD-) were analysed for CD11b and Cd11c expression. Myeloid dendritic cells 
(Mosayebi and Moazzeni, 2011) were defined as CD11b+ CD11chi cells, and 
neutrophils were identified as Ly6G+ cells within the CD11b+ CD11c- population. 
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CD11b+ CD11c- Ly6G- NK1.1- cells were further divided into subpopulations 
according to their Ly6C and F4/80 expression, i.e. macrophages (Ly6C lo F4/80hi) and 
monocytes (Ly6Chi F4/80lo), following Blériot et al. (2015) and Ramachandran et al. 
(2012). All gates were defined by using fluorescence minus one (FMO) controls 
(Supplementary Figure 1).  




Isolation of total RNA and reverse transcription was performed as described 
previously (Kiemer et al., 2009). Real-time quantitative polymerase chain reaction 
(qPCR) was performed in a CFX96 cycler (Bio-Rad, Munich, Germany) with 5× HOT 
FIREPol® EvaGreen® qPCR Mix Plus (Solis BioDyne, Tartu, Estonia). All samples 
were analysed in triplicate. Primers and conditions are listed in Supplementary Table 
1. Efficiency for each experiment was determined using a standard dilution series as 
described previously (Kiemer et al., 2009). The absolute gene expression was 
normalised to Csnk2a2 mRNA values. Csnk2a2 was identified as the most stable 
housekeeping gene out of 3 housekeeping genes according to geNorm 
(Vandesompele et al., 2002) and NormFinder (Andersen et al., 2004).  
 
2.3.4 TLC lipid class analysis 
Thin-layer chromatography (TLC) lipid class analysis was performed as described 
previously (Dembek et al., 2017; Kessler et al., 2016; Laggai et al., 2013). 
 
2.3.5 Fatty Acid Measurement by Gas Chromatography-Mass Spectrometry 
(GC-MS) 
Snap-frozen liver tissue samples were lyophilised (approximately 2 mg dry weight) 
and hydrolysed by the fatty acid methyl ester (FAME) method. Fatty acid 
measurement using gas chromatography–mass spectrometry was performed as 
described previously (Laggai et al., 2014) by Dr. Katja Gemperlein (Department of 
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Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research 
Saarland, Saarbrücken, Germany). 
 
2.3.6 Serum parameters 
Serum levels of cholesterol, high-density lipoproteins (HDL), triglycerides, aspartate 
transaminase (AST), and alanine transaminase (ALT) were determined at the 
‘Zentrallabor des Universitätsklinikums des Saarlandes’ (Saarland University, 
Homburg, Germany).  
 
2.3.7 Caspase-3-like activity assay 
Caspase-3-like activity assay was performed as described previously (Kessler et al., 
2013). Fluorescence was measured 3 h after incubating at 37°C by a GloMax® 
Discover System (Promega, Mannheim, Germany). 
 
2.3.8 TBARS assay 
Quantification of thiobarbituric acid reactive substances (TBARS) was performed as 
described previously (Simon et al., 2014). 
 
2.3.9 Statistical analysis 
Data analysis and statistics of experimental data were performed using the Origin 
software (OriginPro 8.1G; OriginLabs, Northampton, MA, USA). All data are 
displayed as boxplots with 25th/75th percentile boxes, geometric medians (line), 
means (square), and 10th/90th percentiles as whiskers. Statistical differences were 
estimated by independent two-sample t-test or Mann-Whitney test depending on 
normal distribution, which was tested by the Shapiro–Wilk method. All tests are two-
sided, and differences were considered statistically significant when p-values were 
less than 0.05. 
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2.4 Results  
2.4.1 Effects of DEN on leukocytes 
The total amount of leukocytes and their composition in the livers was analysed by 
flow cytometry. The obtained data revealed that the total number of leukocytes 
(CD45+) was significantly higher in the DEN-treated animals (Figure 1A, Table 1). 
Furthermore, the number of myeloid dendritic cells (CD11b+ CD11chi), neutrophils 
(CD11b+ CD11c- NK1.1- Ly6G+), and monocytes (CD11b+ CD11c- NK1.1- Ly6G- 
Ly6Chi F4/80lo) was significantly increased in the DEN-treated animals (Figure 1B, C; 
Table 1). In contrast, the proportion of macrophages (CD11b+ CD11c- NK1.1- Ly6G- 
Ly6Clo F4/80hi) was significantly decreased in the livers of DEN-treated animals 
(Figure 1B, C; Table 1). Therefore, the monocyte / macrophage ratio was highly 
elevated in the DEN-treated mice (Table 1). Since chemokines are important factors 
of leukocyte recruitment, the hepatic mRNA expression of the chemokine (C-X-C 
Motif) ligand 1 (Cxcl1) was analysed and showed increased levels in DEN-treated 
animals. The analysis of the C-type lectin domain family 4, member F (Clec4f), which 
is a specific marker for Kupffer cells (Scott et al., 2016), revealed no differences (p = 
0.62) between the differently treated animals (Figure 1D).  
 


























Figure 1. Effects of DEN on hepatic leukocyte counts and the composition of the myeloid 
compartment. (A): The total amount of CD45 positive cells in liver tissues was determined by flow 
cytometry. (B, C): CD45 positive hepatic cells isolated from NaCl- (B) and DEN- (C) treated mice were 
analysed by flow cytometry. (D): Cxcl1 and Clec4f mRNA expression by qPCR normalised to Csnk2a2 
mRNA. n = 10 for A-C; n = 6 for D. Statistical difference: *: p ≤ 0.05. 
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 mean (NaCl)  SEM (NaCl) mean (DEN)  SEM (NaCl) p-value 
leukocytes  
[% of total hepatic cells] 
0.52 ± 0.049 1.31 ± 0.207 0.002 
myeloid DCs  
[% of leukocytes] 
2.624 ± 0.337 14.605 ± 1.23 1.42E-7 
Neutrophils 
[% of leukocytes] 
2.519 ± 0.351 4.222 ± 0.534 0.016 
macrophages  
[% of leukocytes] 
1.912 ± 0.361 0.969 ± 0.09 0.021 
monocytes  
[% of leukocytes] 
2.969 ± 0.34 17.551 ± 1.736 2.81E-7 













Table 1. Total leukocyte amount [% of total hepatic cells], proportion of myeloid cells [% of 
leukocytes / CD45
+
 cells], and monocyte /macrophage ratio. P-values below 0.05 were considered 
significant. 
 
2.4.2 Effects of DEN on lipids 
Since inflammatory events in the liver are often linked to lipid accumulation, we 
assessed the hepatic lipid composition as well as the serum levels of lipids. Both 
were significantly altered in DEN-treated animals compared to sham-treated mice 
(Figure 2). The amount of hepatic triglycerides was significantly increased, whereas 
none of the other lipid classes showed significant differences between sham-treated 
and DEN-treated mice (Figure 2A). Serum triglyceride levels were significantly 
lowered in these animals (Figure 2B), while serum cholesterol levels were elevated 
(Figure 2B). Serum HDL levels did not differ significantly between both groups 
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Figure 2. Effects of DEN on lipid composition. (A): Hepatic lipid composition: triglyceride (TG), 
cholesterolester (CHE), cholesterol (CH), diglyceride (DG), phosphatidylserine (PS), 
phosphatidylethanolamine (PE), phosphatidylcholine (PC). (B): Triglyceride (TG), cholesterol (CH), 
and  high-density lipoprotein (HDL) serum levels. (C): Composition of fatty acids in liver tissue (1): 
palmitic acid (PA,16:0), stearic acid (SA ,18:0), oleic acid (OA, 18:1), linoleic acid (LLA, 18:2), 
arachidonic acid (AOA , 22:4), docosahexaeinic acid (DHA, 22:6), palmitoleic acid (POA, 16:1), oleic 
acid isomer 2 (OA2, 18:1), eicosatrienoic acid (ETA, 20:3). (D): Composition of fatty acids in liver 
tissue (2): myristic acid (MYA, 14:0), palmitoleic acid isomer 2 (POA2, 16:1), margaric acid (MAA, 
17:0), arachidic acid (AAA,  20:0), gondoic acid (GA, 20:1), eicosadienoic acid (EDA, 20:2), behenic 
acid (BA, 22:0), dicosapentaenoic acid (DPA, 22:5), lignoceric acid (LCA, 24:0), nervonic acid (NA, 
24:1). (E): Proportion of fatty acid classes in liver tissue (S = saturated; MU = monounsaturated; PU = 
polyunsaturated). (F): C16 and C18 fatty acid ratios in liver tissues. n = 6 for A, C-F; n = 16 for B. 
Statistical difference: *: p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 0.001. 
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GC-MS analyses of hydrolysed lipids revealed significantly higher levels of several 
fatty acids in DEN-treated mice (Figure 2C, D). A more pronounced accumulation of 
monounsaturated as well as polyunsaturated fatty acids was observed (Figure 2E). In 
particular, arachidonic acid (C20:4), a precursor of eicosanoids, docosahexaenoic 
acid (C22:6), linoleic acid (C18:2), stearic acid (C18:0), behenic acid (C22:0), 
lignoceric acid (C24:0), and nervonic acid (C24:1) were increased (Figure 2C, D). 
The C16 unsaturated / C16 saturated fatty acid ratio was lowered, and the C18 / C16 
fatty acid ratio was elevated in the livers of DEN-treated animals (Figure 2F). 
To get further insights into the lipogenic effect of DEN, the hepatic mRNA expression 
of several genes involved in lipid metabolism was analysed. The expression of 
carnitine palmitoyltransferase 1 (Cpt1a), which catalyses fatty acid transport into the 
mitochondrion and regulates fatty acid oxidation in the liver (McGarry and Brown, 
1997), was increased in DEN-treated mice. The rate limiting enzyme in the synthesis 
of monounsaturated fatty acids (Miyazaki and Ntambi, 2003) stearoyl-CoA 
desaturase 1 (Scd1), fatty acid binding protein 1 (Fabp1), which enhances cellular 
long chain fatty acid uptake (Guzman et al., 2013), and the key enzyme of de novo 
lipogenesis (Chakravarthy et al., 2007) fatty acid synthase (Fasn) were 
downregulated in livers of DEN-treated mice (Figure 3A). In addition, apolipoprotein 
A-IV (Apoa4), which transports long chain fatty acids as a part of chylomicrons 
(Wang et al., 2015), tended to be upregulated (p = 0.08) in the DEN-treated animals. 
The expression levels of nuclear receptor subfamily 1 group H member 3 (Nr1h3), 
which catalyses cholesterol conversion into bile acids (Kalaany and Mangelsdorf, 
2006), sterol regulatory element-binding transcription factor 1 (Srebf1), which controls 
the expression of fatty acid, phospholipid and triglyceride biosynthetic genes 
(Shimano et al., 1997), sterol regulatory element-binding transcription factor 2 
(Srebf2), which mainly regulates cholesterol biosynthesis (Horton et al., 1998), 
peroxisome proliferator-activated receptor alpha (Ppara), which is a key regulator in 
fatty acid uptake, utilisation, and catabolism (Kersten, 2014), MLX-interacting protein-
like (Mlxipl), which regulates glucose metabolism and the synthesis of fatty acids and 
triglycerides (Iizuka et al., 2004),  and elongation of very long chain fatty acids protein 
6 (Elovl6), which is involved in the elongation of saturated and monounsaturated fatty 
acids (Matsuzaka et al., 2002), were not altered between both groups (Figure 3B).  
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Figure 3. Effects of DEN on hepatic expression of genes involved in lipid metabolism. (A): 
Expression of Cpt1a, Scd1, Fabp1, and Fasn by qPCR (significant differences). (B): Expression of 
Apoa4, Nr1h3, Srebf1, Srebf2, Ppara, Mlxipl, and Elovl6 by qPCR (no significant differences).  n = 6. 
Statistical difference: *: p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 0.001. 
 
2.4.3 Effects of DEN on weight, serum transaminases, ROS, and caspase-3-
like activity 
To determine the amount of liver damage induced by DEN, the serum was analysed 
for the transaminases AST and ALT – two routinely used markers for acute liver 
injury. Both were significantly elevated in the DEN-treated animals (Figure 4A). 
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Figure 4. Effects of DEN on liver injury and hepatic cell death. (A): AST and ALT serum levels. 
(B): Lipid peroxidation in liver tissue by TBARS assay. (C): Liver weight. (D): Liver / body weight ratio. 
(E): Difference in body weight (day of treatment vs day of sacrifice). (F): Apoptosis in liver tissue, 
caspase-3-like activity assay. n = 16 for A; n = 6 for B-F. Statistical difference: *: p ≤ 0.05; **: p ≤ 0.01; 
***: p ≤ 0.001. 
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Since lipid peroxidation is increased in NAFLD (Konishi et al., 2006), we assessed 
lipid peroxidation as a marker for oxidative stress caused by reactive oxygen species 
(ROS). Accordingly, DEN treatment significantly increased lipid peroxidation as 
analysed by TBARS assay (Figure 4B).  
After the treatment, we observed that liver weight and liver-to-body weight ratio were 
distinctly lower in DEN-treated animals. Furthermore, not only the liver but also the 
body weight were significantly decreased in DEN-treated animals (Figure 4C-E). 
In order to determine whether apoptotic or necrotic events play the main role in this 
loss of liver tissue, a caspase-3-like activity assay was performed showing no 
significant difference between both groups (Figure 4F).  
DEN-induced leukocyte recruitment and lipid composition 
32 
2.5 Discussion 
Although the carcinogenic effect of DEN is widely known, the details of the DEN-
induced changes in the liver are not completely understood. It has also been 
suggested that the toxic effects of DEN are strongly dependent on cytokine 
expression of immune cells (Naugler et al., 2007). In the latter study, the authors 
hypothesised that Kupffer cells are the main source of DEN-induced inflammatory 
cytokine expression leading to DEN-induced liver injury. However, they did not 
investigate cytokine expression with and without Kupffer cells in vivo. In our study, 
monocytes were the most abundant fraction in the analysed immune cells, whereas 
the number of macrophages was decreased. Similar results were found in murine 
livers where hepatic inflammation was induced by paracetamol, CCl4, or bacterial 
infection (Blériot et al., 2015; Ramachandran et al., 2012; Zigmond et al., 2014). All of 
these studies report a temporary decline of Kupffer cell numbers. As resident 
macrophages, Kupffer cells show a regulatory and anti-inflammatory phenotype at 
steady state (Blériot et al., 2015). Inflammatory events result in an influx of Ly6Chi 
monocytes, which differentiate into proinflammatory macrophages during the early 
response, thereby driving inflammation.  
Although Maeda et al. (2005) showed that the induction of inflammatory cytokines 24 
h after DEN treatment depends on Kupffer cells, they reported a diminished tumour 
development in mice, which were deficient for the pro-
Kupffer cells and monocytes. Thus, no distinction can be made between the 
contribution of Kupffer cells and monocytes to carcinogenic event. In addition, 
expression of the major chemokine Cxcl1 was increased in DEN-treated animals. In 
alcoholic steatohepatitis CXCL1 is upregulated, thereby promoting neutrophil 
infiltrations (Gao and Tsukamoto, 2016). In a combined alcohol and Western diet, 
Cxcl1 characterises a neutrophilic inflammation (Lazaro et al., 2015). In line with 
these findings, it has been shown that in non-alcoholic steatohepatitis (NASH), the 
number of neutrophils and monocytes is elevated (Liang et al., 2014; Peverill et al., 
2014). In HCC, CXCL1 as well as neutrophils seem to promote tumour progression 
(Cui et al., 2016; Kuang et al., 2011), which underlines the tumour-promoting 
environment created in our model. Concordantly, treatment with an anti-Ly6G 
antibody leads to a reduction in tumour burden of DEN-treated mice (Wilson et al., 
2015).  
DEN-induced leukocyte recruitment and lipid composition 
33 
In inflammatory conditions of the liver, inflammation is usually accompanied and 
triggered by an increased lipid accumulation in hepatocytes independent of the cause 
of inflammation (e.g. viral hepatitis, alcoholic or non-alcoholic steatohepatitis). 
However, differences in the hepatic lipid composition in DEN-induced liver injury have 
not been well characterised so far. Hepatic lipid deposition by DEN has been 
described in fish (Braunbeck et al., 1992). Other studies focused on the qualitative 
lipid composition in DEN-induced liver tumours and did not compare quantities to 
healthy or adjacent normal tissue (Abel et al., 2001; Canuto et al., 1989; Yoshimura 
et al., 2013). In general, in an accumulation of fat in the liver, lipids are mostly 
incorporated in the form of triglycerides (Cohen et al., 2011). Accordingly, serum 
triglyceride levels were lowered in DEN-treated animals, whereas hepatic triglyceride 
levels were increased, suggesting a decreased triglyceride export from the liver. In 
addition, the sum of saturated as well as the sum of polyunsaturated fatty acids were 
increased in the DEN-treated mice indicating a pro-inflammatory environment 
(Nishiyama et al., 2017; von Schacky and Harris, 2007). The DEN-induced elevation 
of the C18/C16 fatty acid ratio has been shown in DEN-treated mice and NASH livers 
(Fengler et al., 2016; Kessler et al., 2014; Laggai et al., 2014, Puri et al., 2007). The 
increased ratio is at least partly due to a dramatic increase of stearic acid (C18:0), 
which has also been shown to be elevated in HCC tissue (Tolstik et al., 2015). 
Corresponding to the decreased ratios of unsaturated to saturated C16 and C18 fatty 
acids, Scd1, being responsible for the desaturation of stearic acid (Miyazaki et al., 
2006), was decreased in the DEN-treated mice.  
Last, Cpt1a, which plays an important role in the beta-oxidation of long chain fatty 
acids, was upregulated in DEN-treated mice. Metabolic disorders like diabetes have 
been shown to be caused by an increased expression but reduction of functional 
activity of CPT1A (Rasmussen et al., 2002). Interestingly, Fabp1, which inversely 
correlates with poor prognosis in HCC (Wang et al., 2014), was downregulated in 
DEN-treated mice. Quite in contrast, Fabp1 knock out mice showed decreased 
hepatic triglyceride levels (Martin et al., 2005). The downregulation of Fasn in DEN-
treated animals may be explained by a possible negative feedback mechanism 
caused by the increased amount of above mentioned fatty acids. Lower Fasn levels 
in hepatic lipid accumulation have been described in different etiologies of steatosis, 
such as NASH and drug-induced steatosis (Laggai et al., 2014; Lelliott et al., 2005; 
Sommer et al., 2017). 
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As commonly known, long-term and short-term models of DEN application induce 
liver injury in rodents (Liu et al., 2009; Qiu et al., 2017; Shirakami et al., 2012). A 
substantial liver injury was supported by the observation that liver weight and liver-to-
body weight ratio were distinctly lower in DEN-treated animals. Accordingly, short-
term treatment with similar doses of DEN in rats resulted in a loss of relative liver 
weight (Barbisan et al., 2002). This might be due to necrosis and hyperaemia taking 
place after short-term treatment with DEN (Liu et al., 2009). A predominant role of 
necrotic events is further supported by the lack of a significant difference in caspase-
3-like activity and strongly increased transaminases after application of DEN 
suggesting a minor involvement of apoptotic events.  
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2.6 Conclusion 
Although it has been shown before that short-term DEN treatment drives severe liver 
injury and acute hepatic inflammation (Liu et al., 2009; Naugler et al., 2007; Park et 
al., 2010), to our knowledge, our report is the first to show its impact on immune cell 
recruitment and hepatic lipid changes. Thus, the DEN short-term approach is a useful 
model to analyse the pathomechanisms and possible interventions in a tumour-
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2.7 Supplementary data 
 
 
Supplementary Figure 1. FMO controls used for flow cytometric gating. 
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gene forward primer 
sequence 5' → 3' 
reverse primer  
sequence 5' → 3' 






























































NM_013839.4 TV1;  
NM_001177730.1 TV2 




















NM_033218.1 61 130 0.25 
 
Supplementary Table 1. Sequences of primers used for murine mRNA expression analysis.
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3 The mRNA-binding protein TTP 
promotes hepatocarcinogenesis but 
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3.1 Abstract 
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-
related death worldwide. The dysregulated expression of mRNA-binding proteins 
(RBPs) can be a key factor in tumour initiation and progression. One of the RBPs, 
which has been shown to be downregulated in several types of cancer, is 
tristetraprolin (TTP, gene name ZFP36). Little is known about the role of TTP in 
hepatic tumour initiation and progression. Using a hepatocyte-specific Ttp knockout 
mouse model and in vitro TTP overexpression, tumour initiation and progression 
were analysed in order to elucidate the mechanistic role of TTP in HCC. 
TTP expression was analysed in three large human data sets (TCGA and GEO) 
comprising up to 369 tumour and non-tumour liver samples. Effects of hepatocyte Ttp 
knockout in male C57BL/6 mice on tumour initiation and inflammation was 
determined via haematoxylin and eosin staining, and flow cytometry. Effects of TTP 
overexpression was analysed via MTT-assay (chemoresistance), scratch assay 
(migration), flow cytometry (proliferation), and qPCR (TTP target identification) in 
human HepG2, PLC/PRF/5, and Huh7 hepatoma cells. In the same cell lines, the 
effects of hypomethylation on TTP expression was determined. 
TTP expression was downregulated in tumour samples of all analysed data sets 
compared to non-tumour or cirrhotic tissue. Ttp knockout mice had a significantly 
decreased tumour burden upon treatment with the carcinogen diethylnitrosamine 
(DEN) and their DEN-induced leukocyte recruitment was altered. Only a minor effect 
of TTP overexpression on chemoresistance was observed in Huh7 cells. However, 
TTP overexpression distinctly decreased migration ability in PLC/PRF/5 and Huh7 
cells, and proliferation in HepG2, PLC/PRF/5, and Huh7. Several oncogenes were 
downregulated in TTP-overexpressing hepatoma cells, e.g. B-cell lymphoma 2 
(BCL2), c-Myc (MYC), and vascular endothelial growth factor A (VEGFA). 
Hypomethylation increased TTP expression in HepG2 and Huh7 cells, but TTP 
promoter methylation was unaltered in human HCC samples. 
Taken together, this study suggests that hepatocyte TTP promotes 
hepatocarcinogenesis, while it shows tumour-suppressive actions in hepatic tumour 
progression.
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3.2 Introduction 
Hepatocellular carcinoma (HCC), the predominant form of liver cancer, is the second 
most common cause of cancer-related death worldwide (Bruix et al., 2015; Tang et 
al., 2017). Most cases of HCC occur in North Africa and East Asia, where HCC is 
mainly induced by chronic hepatitis B and C infection (Farazi and DePinho, 2006). 
Other risk factors are alcohol abuse, whereas in Northern Europe, the USA, and 
Canada, HCC is mainly caused by obesity, type 2 diabetes, and metabolic disorders 
(El-Serag, 2012, Reeves et al., 2016).  
The initiation and progression of cancer are provoked by dysregulated expression of 
proteins controlling diverse cellular phenotypes: cell cycle, differentiation, apoptosis, 
angiogenesis, and cell invasiveness (Hanahan and Weinberg, 2011). Biosynthesis of 
these proteins is strongly regulated by the concentrations of their respective mRNAs 
in the cytoplasm, which depend on both mRNA synthesis and degradation. The 
cytoplasmic stability of many mRNAs is controlled by mRNA-binding proteins (RBPs), 
some of which have been shown to be deregulated in HCC. However, most of the 
studies focus on upregulated RBPs (Dang et al., 2017; Gutschner et al., 2014; 
Kessler et al., 2015; Li et al., 2017). A subgroup of the RBPs are the so-called AU-
rich elements binding proteins (ARE-BPs), which control the stability of mRNAs by 
binding to AU-rich elements (ARE) located within their 3′-untranslated region (3′-
UTR) (Guhaniyogi and Brewer, 2001). On the one hand, some of the ARE-BPs – like 
tristetraprolin (TTP or ZFP36) – accelerate decay of transcripts (Blackshear 2002). 
The strongest evidence for its mRNA-destabilising role could be observed in a Ttp-
deficient mouse model, in which tumour necrosis factor α (Tnf) mRNA was stabilised 
leading to a systemic inflammatory syndrome (Carballo et al., 1998). On the other 
hand, some ARE-BPs – such as human antigen R (HuR or ELAVL1) – protect 
mRNAs from degradation (Baou et al., 2011). Interestingly, TTP expression is 
repressed in several human cancers (Hitti et al., 2016; Sanduja et al., 2012). 
Furthermore, a loss of functional TTP can modulate diverse tumourigenic phenotypes 
(Brennan et al., 2009).  
Although TTP has also been suggested to be downregulated in human liver cancer 
(Hitti et al., 2016) and to be only minimally expressed in human hepatoma cells 
(Sohn et al., 2010), little is known about its possible role in hepatic tumour initiation 
and progression. Therefore, we conducted a detailed study to address these issues. 
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We analysed the effect of a liver specific Ttp knockout in mice treated with a tumour-
inducing agent and checked the impact of TTP overexpression in steps of tumour 
progression including migration, proliferation, and chemoresistance. Our findings 
reveal tumour-promoting actions of TTP in tumour initiation, but tumour-suppressive 
actions in HCC progression. 
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3.3 Materials and Methods 
3.3.1 Animals 
All animal procedures were performed in accordance with the local animal welfare 
committee (permission no. 37/2014). Male C57BL/6 mice were kept under controlled 
conditions regarding temperature, humidity, 12 h day/night rhythm, and food access. 
For the long-term experiment, which mimics hepatocarcinogenesis, 80 wild type and 
80 Ttp knockout (unpublished) two-week-old male mice were intraperitoneally 
injected with either a 5 mg / kg body weight diethylnitrosamine (DEN) solution or a 
0.9% NaCl solution as a sham-control to determine the effects of TTP on hepatic 
tumour initiation. 22 weeks after the injection, the mice were sacrificed. For the short-
term experiment mimicking acute hepatic inflammation, 32 wild type and 32 Ttp 
knockout nine-week-old male mice were intraperitoneally injected with either a 100 
mg / kg body weight DEN solution or with a 0.9% NaCl solution as a sham-control to 
identify possible effects of TTP on acute hepatic inflammation. 48 hours after the 
injection, the mice were sacrificed. Liver specific Ttp knockout was induced via the 
Cre/lox system. In this mice, the Ttp allele was flanked by two loxP sequences, which 
can be detected and cut by the Cre recombinase. To make this knockout hepatocyte 
specific, Cre was linked to the albumin gene (Alb), which is only expressed in the 
liver. The control mice are Cre negative and are therefore able to express the loxP-
flanked Ttp unrestrictedly. Liver specific Ttp knockout was confirmed via qPCR 
(Supplementary Figure 1). Ttp expression was almost absent in hepatocyte-specific 
knockout mice, suggesting that the predominant Ttp expression in the liver is found in 
hepatocytes. The animals were kindly provided by Dr. Perry J. Blackshear (The 
Laboratory of Signal Transduction, Research Triangle Park, NC, USA). 
 
3.3.2 Histology 
For histological analysis, paraffin-embedded liver tissue specimens were cut into 5 
µm sections and stained with haematoxylin and eosin (H&E). This analysis was 
kindly performed by Prof. Dr. Johannes Haybäck (Department of Pathology, Otto-
von-Guericke University, Magdeburg, Germany). 
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3.3.3 Cell culture 
HepG2, PLC/PRF/5, and Huh7cells were cultured in RPMI-1640 medium with 10% 
fetal calf serum, 1% penicillin/streptomycin and 1% glutamine (Sigma-Aldrich, 
Taufkirchen, Germany) at 37°C and 5% CO2.  
 
3.3.4 Transient TTP overexpression   
For overexpression experiments, a vector (pZeoSV2(–)) containing the human TTP 
coding sequence tagged with the human influenza hemagglutinin tag or the vector 
with the antisense sequence as a control (Ref. No.: V855-01, Invitrogen, Carlsbad, 
California, USA) was used. The vector was kindly provided by Prof. Dr. Hartmut 
Kleinert (Fechir et al., 2005) and the sequence was verified by sequencing. Transient 
TTP overexpression in hepatoma cells was established by transfection with the 
vector using jetPEITM Hepatocyte reagent (102-05N, Polyplus transfection, Illkirch, 
France) as recommended by the manufacturer. Successful TTP overexpression was 
confirmed via Western Blot for every experiment. 
 
3.3.5 Cytotoxicity assay  
Hepatoma cells were seeded into 96-well plates, transfected with TTP or control 
vector, and treated with different concentrations of doxorubicin (Sigma-Aldrich) or 
sorafenib (Biomol GmbH, Hamburg, Germany) and the respective solvent control. 24 
h after the treatment, the cytostatic substances were removed and 5 mg/ml MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazolium bromide; thiazolyl blue) (Sigma-
Aldrich) in medium were added. After 2 h incubation, the formazan crystals were 
solved in dimethyl sulfoxide and the absorbance was measured at 550 nm with 690 
nm as reference wavelength in a microplate reader (Tecan Sunrise™, Tecan Group 
Ltd., Männedorf, Switzerland). 
 
3.3.6 Migration assay  
Cells were seeded into 12-well plates, transfected with TTP or control vector, and 
scratched 48 h after transfection with a pipet tip. The first image was taken 
immediately after the scratch; the second image was taken 24 h after the scratch. 
Images were obtained and analysed with an Axio Observer Z1 epifluorescence 
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microscope equipped with an AxioCam Mrm (Zeiss, Oberkochen, Germany) using a 
5x objective. Data was analysed with the TScratch software (CSElab, Zürich, 
Switzerland). 
 
3.3.7 Hypomethylation assay  
HepG2, PLC/PRF/5, and Huh7 cells were treated with decitabine over 3 days. The 
DNA-methyltransferase inhibitor (Sigma-Aldrich) was freshly added daily. 
 
3.3.8 Human HCC analysis 
Paraffin-embedded liver samples (n = 31) from randomly selected pseudonymised 
HCC patients who underwent liver resection at the Saarland University Medical 
Center between 2005 and 2010 were obtained as described previously (Kessler et 
al., 2013). The study protocol was approved by the local Ethics Committee (47/07). 
Samples had a mixed aetiology including non-alcoholic steatohepatitis (NASH), 
alcoholic liver disease, viral hepatitis, hemochromatosis, porphyria, and cryptogenic 
cirrhosis (Kessler et al., 2013). 
For differential TTP expression between tumour (n =247) and non-tumour (n = 239) 
samples, the log2 of an RMA-normalised data set (GSE14520) of an 
AffymetrixGeneChip HG-U133A 2.0 was analysed. Similarly, differential gene 
expression was analysed in data set GSE25097 between healthy (n = 6), cirrhotic (n 
= 40), adjacent non-tumour (n = 243), and tumour tissue (n = 268), in data set 
GSE5975 between positive (n = 95) and negative (n = 143) EpCAM samples, and in 
data set GSE20238 between vascular invasive (n = 45) and non-invasive (n = 34) 
HCC samples. Differential expression analysis was based on the Kolmogorov–
Smirnov test. Pearson correlation was applied to detect correlations between genes 
of interest. These data were kindly compiled and analysed by Dr. Ahmad Barghash 
(School of Electrical Engineering and Information Technology, German Jordanian 
University, Amman, Jordan). 
The RNAseq expression data from The Cancer Genome Atlas (TCGA) pan cancer 
dataset comparing TTP expression in tumour and non-tumour liver tissue was 
produced via Toil (Vivian et al., 2017). RSEM (Li and Dewey, 2011) reported 
transcripts per million values were downloaded via the UCSC Xena Browser 
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(https://xenabrowser.net) and comprised 369 primary solid tumour as well as 50 
matched non-tumour tissue samples. These data were kindly compiled and analysed 
by Dr. Markus List (Department of Computational Biology and Applied Algorithmics, 
Max Planck Institute for Informatics, Saarbrücken, Germany). 
TCGA analysis of DNA methylation in HCC was performed as described before 
(Kessler et al., 2015). The data set contained 41 non-tumour and 95 tumour samples. 
We considered methylation only in the promoter regions (defined within 2,000 bp 
upstream of the transcription start site provided in The Eukaryotic Promoter Database 
(EPD)). Averages were considered for regions covered by multiple probes. These 
data were kindly compiled and analysed by Dr. Ahmad Barghash (School of Electrical 




Isolation of human total RNA and reverse transcription was performed using the High 
Pure RNA Isolation Kit or the High Pure RNA Tissue Kit (Roche Diagnostics, 
Mannheim, Germany) and the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, California, USA) according to the manufacturers’ 
instructions. Real-time quantitative polymerase chain reaction (qPCR) was performed 
in a CFX96 cycler (Bio-Rad, München, Germany) with 5× HOT FIREPol® 
EvaGreen® qPCR Mix Plus (Solis BioDyne, Tartu, Estonia). All samples were 
estimated in triplicate. Primers and conditions are listed in Supplementary Table 1. 
Efficiency for each experiment was determined using a standard dilution series as 
described previously (Kiemer et al., 2009). The absolute gene expression was 
normalised to ACTB (for human samples) or Csnk2a2 (for murine samples) mRNA 
values. 
 
3.3.10   Flow cytometry 
Flow cytometric analysis of murine liver leukocyte composition was performed as 
described previously (Wang et al., 2011; Chapter 2.3.2). To determine the amount of 
leukocytes, 1 µg of the FITC mouse anti-mouse CD45.2 Clone 104 antibody 
(#561874, BD Biosciences, Heidelberg, Germany) was used. To detect the 
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composition of leukocytes, 0.5 µg of each antibody were added: APC rat anti-mouse 
Ly6G Clone 1A8 (#560599), APC-R700 rat anti-mouse CD11b Clone  M1/70 
(#564985), BV421 rat anti-mouse Ly6C Clone  AL-21 (#562727), BV510 mouse anti-
mouse NK 1.1 Clone  PK136 (#563096), PE hamster anti-mouse CD11c Clone  HL3 
(#55740, all from BD Biosciences), and FITC human anti-mouse F4/80 clone 
REA126 (#130-102-327 from Miltenyi, Bergisch Gladbach, Germany). To determine 
the composition of the leukocytes, the following gating strategy was applied: FSClow 
debris and erythrocytes, and multiplets with a non-linear SSC-A/SSC-H ratio were 
excluded. Viability was determined by 7-AAD staining. Viable cells (7-AAD-) were 
analysed for CD11b and Cd11c expression. Myeloid dendritic cells (Mosayebi and 
Moazzeni, 2011) were defined as CD11b+ CD11chi cells, and neutrophils were 
identified as Ly6G+ cells within the CD11b+ CD11c- population. CD11b+ CD11c- 
Ly6G- NK1.1- cells were further divided into subpopulations according to their Ly6C 
and F4/80 expression, i.e. macrophages (Ly6Clo F4/80hi) and monocytes (Ly6Chi 
F4/80lo), following Blériot et al. (2015) and Ramachandran et al. (2012). All gates 
were defined by using fluorescence minus one (FMO) controls. Flow cytometric 
analysis of human hepatoma cell proliferation was performed as described previously 
(Schultheiß et al., 2017) using the PE Mouse Anti-Human Ki-67 Set (#5113743, BD 
Biosciences). The isolation and gating strategy was established in collaboration with 
Dr. Jessica Hoppstädter. 
 
3.3.11   Statistical analysis 
Data analysis and statistics of experimental data were performed using the Origin 
software (OriginPro 8.1G; OriginLabs, Northampton, MA, USA). All data are 
displayed either as columns with mean values±SEM or as individual values and 
boxplots±interquartile range with mean (square) and median (line). Statistical 
differences were estimated by independent two-sample t-test or Mann-Whitney test 
depending on normal distribution, which was tested by the Shapiro–Wilk method, or 
Fisher-exact test for categorical data. All tests are two-sided, and differences were 
considered statistically significant when p-values were less than 0.05.
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3.4 Results  
3.4.1 TTP expression in human HCC tissue 
Since TTP has been shown to be downregulated in different human cancer types 
(Sanduja et al., 2012) an extensive expression analysis of TTP in HCC was 
performed. We analysed TTP expression in a microarray data set comprising almost 
250 human HBV-derived HCC samples. The data revealed that the vast majority of 
HCC tissues exhibited much lower TTP mRNA levels than the non-tumour tissue 
(Figure 1A). A TCGA data comprising 369 HCC (primary solid tumour) to 50 non-
tumour liver tissue also showed a substantially decreased expression of TTP in HCC 
tissue (Figure 1B). Moreover, a data set comparing HCC tissue to healthy, cirrhotic, 
and non-tumour tissue of HCC patients revealed decreased levels of TTP mRNA in 
HCC but not in cirrhosis (Figure 1C). Besides the analyses of these publicly available 
–omics datasets, we analysed TTP mRNA expression by qPCR in a set of human 
liver tumour samples from mixed aetiologies and revealed the same results (Figure 
1D). 
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Figure 1. TTP expression in human tumour and non-tumour liver tissue. (A): TTP expression in 
247 human HCC samples relative to the mean of 239 non-tumour liver tissue samples (µ normal) 
(GSE14520). (B): TTP expression in tumour (n = 369) and non-tumour (n = 50) tissue (TCGA). (C): 
TTP expression in healthy, cirrhotic, adjacent non-tumour, and tumour liver tissues (500 samples; 
GSE25097). (D): TTP mRNA levels isolated of tumour and adjacent non-tumour tissues (n = 31). 
Statistical difference: **: p ≤ 0.01; ***: p ≤ 0.001. 
 
3.4.2 Effects of TTP on tumour initiation  
Since TTP was strongly downregulated in human HCC tissue, liver specific Ttp 
knockout mice were generated to test the hypothesis that this knockout will promote 
tumourigenesis. Ttp knockout and wild type mice were treated with DEN at the age of 
two weeks to induce tumours and were sacrificed at the age of six months. In 
contrast to our hypothesis, however, the tumour incidence was significantly lower in 
the DEN-treated Ttp knockout animals compared to the DEN-treated wild type 
animals (Fig 2A) while there was no statistical difference regarding tumour incidence 
between the genotypes in the sham-treated groups. In addition, the number of 
tumours per animal was significantly decreased in the DEN-treated Ttp knockout 
mice compared to the DEN-treated wild type mice (Fig 2B, C). Almost half of the 
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tumours of the sham-treated wild type animals grew trabecular or mixed, whereas all 
other tumours were solid (Fig 2D). The histological evaluation of inflammatory 
infiltrates revealed no difference between the different groups (Fig 2E-G). 




Figure 2. Amount and pattern of tumours and inflammation in DEN- or sham-treated wild type 
(WT) and Ttp knockout (KO) mice. (A): tumour incidence. (B, C): tumour multiplicity. (D): 
predominant tumour growth pattern. (E): portal inflammation. (F): lobular granulocytic inflammation. 
(G): lobular lymphocytic inflammation (Scoring: none, <2, 2-4, or >4 visible at least in one area with a 
20x objective). n = 18 (WT/control), 19 (WT/DEN), 20 (KO/control), 17 (KO/DEN). Statistical 
difference: *: p ≤ 0.05. 
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3.4.3 Effects of TTP on DEN-induced leukocyte recruitment  
DEN-induced hepatocarcinogenesis is typically characterised by inflammatory events 
(Naugler et al., 2007) and, TTP has been suggested to affect leukocyte recruitment 
(Ghosh et al., 2010). We therefore hypothesised that protection from DEN-induced 
liver cancer in Ttp knockout mice is facilitated via attenuated leukocyte recruitment. 
Therefore, the amount of leukocytes inside the liver as well as their composition were 
analysed in the above described long-term DEN experiment via flow cytometry. The 
DEN-treated wild type mice showed an increased number of leukocytes compared to 
their sham-treated controls as assessed by staining for the pan-leukocyte marker 
CD45 (Wang et al., 2011). No difference due to Ttp knockout was observed (Figure 
3A). The amount of macrophage and monocyte was decreased in DEN-treated Ttp 
knockout mice compared to DEN-treated wild type mice, and neutrophils also tended 
(p = 0.06) to be decreased (Figure 3B). No statistical effect on myeloid dendritic cells 
and the monocytes / macrophages ratio could be observed in all groups (Figure 3B, 
C). 
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Figure 3. Effects of DEN on the hepatic amount and composition of leukocytes in wild type 
(WT) and Ttp knockout (KO) mice. Leukocyte number and composition was analysed by multi-color 
flow cytometry. (A): Total amount of CD45 positive cells (long-term experiment). (B): The proportion of 
myeloid dendritic cells (myeloid DCs), neutrophils, macrophages, and monocytes within CD45 positive 
cells was evaluated (long-term experiment). (C): Monocyte / macrophage ratio of CD45 positive cells 
(long-term experiment). (D): Total amount of CD45 positive cells (short-term treatment). (E): 
Composition of CD45 positive cells, i.e. myeloid dendritic cells (myeloid DCs), neutrophils, 
macrophages, and monocytes (long-term experiment). (F): Monocyte / macrophage ratio of CD45 
positive cells (long-term experiment).  n = 10. Statistical difference: *: p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 
0.001. 
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To elucidate the impact of TTP on acute hepatic inflammation as initiating event in 
hepatocarcinogenesis (Kessler et al., 2015; Kessler et al., 2014; Naugler et al., 
2007), Ttp knockout and wild type mice were treated with a high dose of DEN at the 
age of nine weeks to induce inflammation and were sacrificed 48 h after the 
treatment. First, the amount of leukocytes inside the liver as well as their composition 
were analysed. DEN increased the total amount of leukocytes and increased the 
composition of myeloid dendritic cells, neutrophils, and monocytes in Ttp knockout 
and wild type animals in a similar way (Figure 3D, Figure 3E). However, the 
proportion of macrophages was decreased in DEN-treated wild type mice compared 
to their control, whereas no difference could be observed between sham- and DEN-
treated Ttp knockout mice (Figure 3E). DEN treatment also increased the monocyte / 
macrophage ratio, but the effect was reduced in Ttp knockout mice compared to wild 
type mice (Figure 3F).  
 
3.4.4 Effects of TTP on chemoresistance 
In order to clarify the role of TTP during tumour progression, TTP expression was 
investigated with respect to chemoresistance. TTP-overexpressing as well as control 
HepG2, PLC/PRF/5 and Huh7 cells were treated with different concentrations of 
sorafenib and doxorubicin. The results suggested a strong impact of TTP 
overexpression on chemosensitivity in all three cell lines (Figure 4A-F). However, the 
viability of untreated TTP-overexpressing cells was significantly lower than the 
number of untreated control cells in all three cell lines (Figure 4A-F). Therefore, the 
evaluation was adjusted in a way that TTP-overexpressing and control cells were 
normalised to the control cells. This revealed a less dramatically decreased but still 
significantly different chemoresistance (Supplementary Figure 2). Due to this effect of 
TTP on chemoresistance in hepatoma cells, we wondered whether TTP expression 
was related to EpCAM expression in HCC, since EpCAM has been suggested as a 
marker for HCC chemoresistance (Noda et al., 2009). Therefore, we analysed the 
expression of TTP in EpCAM positive vs EpCAM negative HCC tissues but found no 
differences (p = 0.29; Supplementary Figure 3).  
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Figure 4. Effects of TTP overexpression on chemoresistance in hepatoma cells. Cells were 
transfected with either a TTP or a control vector. 24 h after transfection, cells were treated with 
different concentrations of doxorubicin (0 µg/ml, 2.5 µg/ml, 5 µg/ml, 10 µg/ml, 50 µg/ml, 100 µg/ml) or 
sorafenib (0 µM, 1.25 µM, 2.5 µM, 5 µM, 10 µM, 15 µM, 20 µM). Cell viability was determined via MTT 
assay. (A): HepG2 cells treated with doxorubicin. (B): HepG2 cells treated with sorafenib. (C): Huh7 
cells treated with doxorubicin. (D): Huh7 cells treated with sorafenib. (E): PLC/PRF/5 cells treated with 
doxorubicin. (F): PLC/PRF/5 cells treated with sorafenib. n = 3; quadruplicates. Statistical difference: *: 
p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 0.001. 
 
TTP in hepatocarcinogenesis and HCC progression 
56 
3.4.5 Effects of TTP on proliferation 
The MTT assay in TTP-overexpressing cells suggested anti-proliferative actions of 
TTP. We therefore aimed to test the hypothesis of anti-proliferative actions of TTP by 
MKI67 staining and flow cytometry in stably overexpressing cell lines. However, cells 
transfected with the overexpressing plasmid did not grow at all. Thus, proliferation 
ability of transient TTP-overexpressing cells was investigated. The proliferation in 
HepG2, PLC/PRF/5, and Huh7 cells was dramatically decreased after TTP 
overexpression (Figure 5A, B).  
 
Figure 5. Proliferation of TTP-overexpressing hepatoma cells. (A): Proliferation of cells transfected 
with either a TTP or a control vector. (B): Flow cytometric analysis of the proliferation marker MKI67 in 
TTP-overexpressing (TTP) and control cells (control vector). The isotype controls represent the control 
cells. Representative histograms of MKI67 flow cytometric analyses are shown. n = 3; triplicates.  
Statistical difference: *: p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 0.001. 
 
3.4.5 Effects of TTP on migration 
Due to the dramatic impact of TTP on proliferation, we hypothesised that TTP might 
also influence the migration ability in hepatoma cells. Therefore, a scratch assay was 
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performed. The migration ability of PLC/PRF/5 and Huh7 cells, but not of HepG2 
cells was inhibited by TTP (Figure 6A-D).  
 
Figure 6. Migration of TTP-overexpressing hepatoma cells. (A): Migration of cells transfected with 
either a TTP or a control vector. (B-D): Representative images of transfected HepG2 (B), PLC/PRF/5 
(C), and Huh7 cells (D). Images were taken with a 5x objective immediately after the scratch (t (0)) or 
24 h after the scratch (t (24)). For better visualisation, lines indicating overgrown areas were inserted. 
n = 5-6; quadruplicates. Statistical difference: *: p ≤ 0.05.  
 
3.4.6 Genes affected by TTP 
Since TTP represents an mRNA destabilising factor, we hypothesised that TTP’s 
tumour-supressing actions were caused by an altered expression of its target genes, 
i.e. that TTP overexpression resulted in a downregulation of oncogenes. Therefore, 
the expression of the oncogenes B-cell lymphoma 2 (BCL2), c-Myc (MYC), 
transcription factor E2F1 (E2F1), vascular endothelial growth factor A (VEGFA), and 
X-linked inhibitor of apoptosis protein (XIAP), which have been shown to be TTP 
targets in non-liver tissues (Wang et al., 2016; Selmi et al., 2015), was checked. To 
confirm the validity of these targets, we analysed the sequences of their 3’-UTRs and 
found TTP binding-motifs (Mukherjee et al., 2014) in abundance (Supplementary 
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Material 1). Interestingly, AREs could also be found in several yet unknown TTP 
targets, which had been suggested as tumour promoters and were therefore also 
analysed in TTP-overexpressing cells. One of them is the long transcript variant of 
nuclear enriched abundant transcript 1 (NEAT1_v1/v2), NEAT1_v2 (Supplementary 
Material 1). NEAT1 is one of the least stable long non-coding RNAs (Clark et al., 
2012), a presumed tumour promoter, and associated with chemoresistance (Adriaens 
et al., 2016; Guo et al., 2015). Two other ARE containing genes represent RBPs 
themselves: the insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) and 
the insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) (Supplementary 
Material 1), which both promote hepatic tumour progression (Gutschner et al., 2014; 
Jeng et al., 2008). Last, the expression of the TTP antagonist HuR (ELAVL1) was 
determined (Wang et al., 2016). In HepG2 and Huh7 cells, all analysed genes tended 
to be lower expressed after TTP overexpression (Figure 7A, B). MYC, IGF2BP3, and 
VEGFA were significantly lowered in TTP-overexpressing HepG2 cells (Figure 7A). In 
TTP-overexpressing Huh7 cells, IGF2BP1 was the only gene that was significantly 
decreased (Figure 7B). BCL2, IGF2BP1, NEAT1_v2, and VEGFA were significantly 
lowered in PLC/PRF/5 cells (Figure 7C). The expression of HuR showed no statistical 
difference in all three cell lines (Figure 7A-C). Since VEGFA, a promoter of invasion 
in HCC (Li et al., 1998), was lower expressed in HepG2 and PLC/PRF/5 cells, we 
hypothesised that TTP might play a role in HCC vascular invasion. Therefore, TTP 
expression was determined in human HCC samples showing vascular invasion 
compared to samples without vascular invasion. In fact, the results show a 
significantly decreased TTP expression in tissues showing vascular invasion (Figure 
7D). 
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Figure 7. Oncogene expression in TTP-overexpressing hepatoma cells and TTP expression in 
invasive vs non-invasive HCC. Expression levels normalised to cells treated with a control vector 
were determined in HepG2 (A), Huh7 (B), and PLC/PRF/5 cells (C) by qPCR. BCL2 was not 
determined in Huh7 cells since mRNA expression was below the detection limit. n = 3; triplicates. (D): 
TTP expression in human HCCs grouped into tumours positive (n = 45) or negative (n = 34) regarding 
vascular invasion (GSE20238). Statistical difference: *: p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 0.001.  
 
3.4.7 TTP expression in hypomethylated hepatoma cells and promoter 
methylation 
It has been supposed that TTP is regulated via methylation of its promoter and that 
treatment with the DNA methyltransferase inhibitor azacytidine increases TTP 
expression in Huh7 cells but does not affect TTP expression in HepG2 and 
PLC/PRF/5 cells (Sohn et al., 2010). To confirm these results, we treated these three 
cell lines with the more potent inhibitor decitabine (Hollenbach et al., 2010). As 
shown before, no significant effect after treatment could be seen in PLC/PRF/5 cells 
(Figure 8A). In Huh7 cells, TTP expression could be induced upon decitabine 
treatment (Figure 8A). An elevated expression of TTP at multiple concentrations 
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could also be observed in HepG2 cells (Figure 8A). Elevated levels of the 
epigenetically regulated lncRNA H19 in all three cell lines served as a positive control 
(Supplementary Figure 4; Schultheiß et al., 2017). 
Since differences in TTP expression regarding methylation could be observed in two 
of the three analysed hepatoma cell lines, a TCGA data set comprising 50 normal 
and 109 tumour samples was analysed comparing methylation levels of the TTP 
promoter in hepatic tumour and non-tumour tissue. The analysis of the TCGA data 
set, however, revealed no difference regarding the TTP promoter methylation 
between non-tumour and tumour tissue (p = 0.51) (Figure 8B).  
 
Figure 8: Effects of hypomethylation on TTP expression in hepatoma cells and TTP promoter 
methylation in liver tissue. (A): TTP mRNA expression levels in HepG2, PLC/PRF/5, and Huh7 cells 
treated with decitabine. The effect of decitabine was not determined in HepG2 cells at concentrations 
above 1 µM and in Huh7 cells at concentrations above 0.5 µM due to its toxicity. n ≥ 2, duplicates. (B) 
TTP promoter methylation in human liver tumour (n=95) and non-tumour (n=41) samples (TCGA). 
Statistical difference: * p < 0.05.  
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3.5 Discussion 
It is known that TTP expression is frequently repressed in different human cancers 
(Hitti et al., 2016; Sanduja et al., 2012) and that a loss of functional TTP can 
modulate diverse tumourigenic phenotypes (Brennan et al., 2009). In this study, we 
were able to confirm a strong downregulation of TTP in HCC tissues in three large 
cohorts and in a smaller set of human liver tumour compared to adjacent non-tumour 
samples as previously suggested by others (Hitti et al., 2016). Therefore, we 
hypothesised that a hepatic knockout of Ttp might increase the amount of tumours in 
murine livers. However, Ttp knockout animals showed a lower number of tumours 
compared to the wild type animals.  
Although total Ttp knockout mice show a severe inflammatory phenotype (Carbello et 
al., 1998), a hepatocyte-specific knockout of Ttp seems to have a rather inhibitory 
effect on inflammation as observed in the short-term mouse experiment, where the 
amount of macrophages was unaltered, whereas the monocytes / macrophages ratio 
of DEN-treated knockout mice was decreased compared to the DEN-treated wild 
type mice. A temporary increase of monocytes accompanied by a decrease of 
resident liver macrophages is well described in other models inducing hepatic 
inflammation (Blériot et al., 2015; Ramachandran et al., 2012; Zigmond et al., 2014). 
In the long-term experiment, the amount of macrophages and monocytes was 
decreased in the DEN-treated Ttp knockout mice compared to wild type mice. This 
may be explained by the presence of repopulating Kupffer cells of monocyte origin in 
the DEN-treated wild type mice following monocyte infiltration during acute 
inflammation (Blériot et al., 2015; Scott et al., 2016; Zigmond et al., 2014). DEN-
treated Ttp knockout mice did not show such a compensatory effect because the 
amount of macrophages was probably not decreased in acute inflammation as 
indicated by the unaltered proportion of macrophages in DEN-treated Ttp knockout 
mice compared to sham-treated knockout mice in the short-term experiment. 
Although TTP knockdown has been shown to induce monocyte infiltration into 3D 
tumour spheroids and macrophage infiltration into xenograft-induced murine breast 
cancer (Milke et al., 2013), our data rather suggest that hepatocytic TTP promotes 
tumourigenesis by driving proinflammatory monocyte infiltration and thus 
inflammation.  
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Interestingly, the distinct decrease of TTP expression in tumour but not in cirrhotic 
tissue suggests TTP as a useful marker detecting the progression from cirrhotic state 
to malignancy.  
An important role of TTP in hepatic tumour progression is supported by its decreased 
expression in vascularised HCC tissue. This and the fact that VEGFA – an important 
factor for vascularisation and  reported target of TTP in colon cancer (Claesson-
Welsh and Welsh, 2013; Wang et al., 2016) – was downregulated in TTP-
overexpressing hepatoma cells, indicate that TTP might play a role in the 
vascularisation ability of liver cancer, which is a hallmark in the beginning of tumour 
progression (Hanahan and Weinberg, 2011). 
It is well known that cell migration is a critical factor for cancer metastasis (Vicente-
Manzanares and Horwitz, 2011), which may occur in the early stages of tumour 
progression (Balic et al., 2006; Li et al., 2007). TTP has been shown to inhibit the 
migration ability in prostate cancer, ovarian cancer, gastric cancer, and head and 
neck squamous cell carcinoma cells (Lee et al., 2014; van Tubergen et al., 2011; 
Wang et al., 2016; Yoon et al., 2016). Additionally, TTP was suggested to decrease 
the metastatic potential in breast cancer (Al-Souhibani et al., 2010). In this study, we 
were able to show that overexpression of TTP also inhibited the migration ability and 
proliferation in hepatoma cells. A negative effect of TTP on proliferation has been 
shown before in non-hepatic cells, such as gastric cancer, pancreatic cancer, 
melanoma and glioma cells (Wang et al., 2016), but – to our knowledge – we are the 
first to show these effects in hepatic cells. This inhibition of proliferation may be a 
major reason why a stable overexpression of the TTP-containing plasmid was not 
possible to establish in HepG2, Huh7, and PLC/PRF/5 cells. 
TTP has been shown to downregulate several well-established markers for tumour 
progression like BCL2, VEGFA, and MYC in non-liver tissue (Wang et al., 2016). In 
line with these findings, we observed a decreased expression of MYC and VEGFA in 
HepG2 cells, and a decreased expression of BCL2 and VEGFA in PLC/PRF/5, cells 
which were overexpressing TTP. Since HuR stabilises all of the above mentioned 
genes (Baou et al., 2011; Chai et al., 2016), an inhibition of HuR by TTP may result in 
the same effects. However, the unaltered expression of HuR in these cells suggests 
an HuR-independent mechanism. The different expression levels of the analysed 
genes comparing the three cell lines might be explained by the distinct heterogeneity 
of liver cancer itself (Li and Wang, 2016). According to this, the three analysed cell 
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lines also have rather different phenotypes (Ghasemi et al., 2013; Hsu et al., 1993; 
Kanno et al., 2015). 
Chemoresistance is widespread in HCC and another important factor for tumour 
progression (Wörns et al., 2009). We hypothesised that chemoresistance may also 
be affected by TTP, since many of its downstream targets (e.g., BCL2, VEGFA, and 
MYC) are associated with a poor chemosensitivity (Wang et al., 2016). In addition, 
PLC/PRF/5 cells showed a decreased expression of the long transcript variant of the 
long-non coding RNA NEAT1, NEAT1_v2. Interestingly, NEAT1 has been reported to 
enhance chemoresistance in different cancer cell lines, including hepatoma cells 
(Adriaens et al., 2016; unpublished data). Since there are only few studies 
addressing the role of TTP in chemoresistance (Wang et al., 2016), we analysed the 
effect of an approved drug for systemic liver cancer therapy, sorafenib, as well as the 
effect of doxorubicin, which is widely used in chemoembolization (Dhanasekaran et 
al., 2010; Wörns et al., 2009) on TTP-overexpressing hepatoma cells. Our data show 
that overexpression of TTP distinctly decreases the viability of hepatic Huh7 cells 
after doxorubicin or sorafenib treatment, but alters chemosensitivity in HepG2 and 
PLC/PRF/5 cells to a lower extent. The unaltered expression of TTP in EpCAM 
positive – a marker for HCC chemoresistance (Noda et al., 2009) – compared to 
EpCAM negative HCC tissues supports a less important role of TTP in HCC 
chemoresistance.  
Regarding the regulation of TTP in HCC, previous findings suggested that 
methylation of the TTP promoter is a key factor in its downregulation in hepatoma 
cells (Sohn et al., 2010; Tran et al., 2016). In line with previous findings, we could 
detect an increased TTP expression in Huh7 and an unaltered TTP expression in 
PLC/PRF/5 cells treated with decitabine (Sohn et al., 2010; Tran et al., 2016). In 
contrast to Sohn’s results, we were also able to show an increased TTP expression 
in the hypomethylated HepG2 cells, which may be explained by the higher potency of 
decitabine compared to azacytidine (Hollenbach et al., 2010). This assumption is 
supported by the increased expression of H19 in decitabine-treated PLC/PRF/5 cells, 
which was not observed in the azacytidine-treated PLC/PRF/5 cells (Schultheiß et al., 
2017). Sohn et al. (2010) also described an increased methylation at a single CpG 
site in HCC samples compared to non-tumour samples (n =24). Still, our analysis of 
TTP methylation in the whole promoter region of human liver tissue showed no 
difference between non-tumour (n = 41) and tumour tissue (n = 95). Interestingly, 
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another study shows that TTP expression is regulated by histone deacetylases 
(HDACs) and not by DNA methylation in colon cancer cells (Sobolewski et al., 2015). 
HDACs promote transcriptional repression and have been associated with silencing 
of many tumour suppressor genes, since many HDACs are overexpressed in cancer 
(Sobolewski et al., 2015). Therefore, also in the liver TTP expression might not only 
be influenced by its promoter methylation but by HDACs. 
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3.6 Conclusion 
Our data suggest that hepatocytic TTP plays an inflammation-dependent role in 
promoting hepatic tumour initiation but has a major negative effect on hepatic tumour 
progression. In addition, TTP may be a useful marker detecting the progression from 
cirrhosis towards HCC. 
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Supplementary Figure 1: Ttp mRNA levels in Ttp knockout and wild type animals. Ttp / Csnk2a2 
mRNA ratio in wild type (WT) and knockout (KO) animals injected with NaCl. n = 6. Statistical 
difference: ** p ≤ 0.01. 
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Supplementary Figure 2. Effects of TTP overexpression on chemoresistance in hepatoma cells 
(normalised to control vector). Cells were transfected with either a TTP or a control vector. 24 h 
after transfection, cells were treated with different concentrations of doxorubicin (0 µg/ml, 2.5 µg/ml, 5 
µg/ml, 10 µg/ml, 50 µg/ml, 100 µg/ml) or sorafenib (0 µM, 1.25 µM, 2.5 µM, 5 µM, 10 µM, 15 µM, 20 
µM). Cell viability was determined via MTT assay. Both groups (TTP and control vector) are 
normalised to the viability of the control vector transfected cells without addition of doxorubicin or 
sorafenib (=100%). (A): HepG2 cells treated with doxorubicin. (B): HepG2 cells treated with sorafenib. 
(C): Huh7 cells treated with doxorubicin. (D): Huh7 cells treated with sorafenib. (E): PLC/PRF/5 cells 
treated with doxorubicin. (F): PLC/PRF/5 cells treated with sorafenib. n = 3; quadruplicates. Statistical 
difference: *: p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 0.001. 
 















Supplementary Figure 3. TTP expression in EpCAM-positive (n = 95) and EpCAM-negative (n = 




































Supplementary Figure 4: Effects of hypomethylation on H19 expression in hepatoma cells. H19 
mRNA expression levels in HepG2 (A), PLC/PRF/5 (B), and Huh7 (C) cells treated with decitabine. 
The effect of decitabine was not determined in HepG2 cells at concentrations above 1 µM and in Huh7 
cells at concentrations above 0.5 µM due to its toxicity. n ≥ 2, duplicates. Statistical difference: * p < 
0.05, ** p < 0.01.  
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Supplementary Material 1: ARE in TTP target genes.  
The following motifs are enriched in TTP targets (Mukherjee et al., 2014): ATTTA 
(blue), TTTTT (yellow), CTTTT (fat), TTTTC (bordeaux), CTTTC (purple), TATTTATT 
(green), TTATTTATT (underlined) and TATT (orange).  
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4 Hepatocellular carcinoma and 
nuclear paraspeckles: induction in 
chemoresistance and prediction for 
poor survival 
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4.1 Abstract 
Hepatocellular carcinoma (HCC) represents the second most common cause of 
cancer-related death worldwide, not least due to its high chemoresistance. The long 
non-coding RNA nuclear paraspeckle assembly transcript 1 (NEAT1), localised in 
nuclear paraspeckles, has been shown to enhance chemoresistance in several 
cancer cells. Since data on NEAT1 in HCC chemosensitivity are completely lacking 
and chemoresistance is linked to poor prognosis, we aimed to study NEAT1 
expression in HCC chemoresistance and its link to HCC prognosis.  
NEAT1 expression was determined in either sensitive, sorafenib, or doxorubicin 
resistant HepG2, PLC/PRF/5, and Huh7 cells by qPCR. Paraspeckles were detected 
by immunofluorescence staining of paraspeckle component 1 (PSPC1). The 
expression of transcript variants of NEAT1 and of the paraspeckle-associated 
proteins PSPC1, non-POU domain containing octamer binding protein (NONO), and 
RNA-binding motif protein 14 (RBM14) was analysed in the TCGA liver tissue data 
set. 
NEAT1 was overexpressed in all three sorafenib and doxorubicin resistant cell lines. 
Paraspeckles were present in all chemoresistant cells, whereas no signal was 
detected in the sensitive cells. NEAT1 as well as transcripts encoding PSPC1, 
NONO, and RBM14 were increased in tumour tissue. PSPC1, NONO, and RBM14 
transcripts highly correlated with poor survival, whereas NEAT1 did not. 
Our data show an induction of NEAT1 in HCC chemoresistance and a high 
correlation of transcripts encoding paraspeckle-associated proteins with poor survival 
in HCC. Therefore, NEAT1, PSPC1, NONO, and RBM14 might be promising targets 
for novel HCC therapies, and the paraspeckle-associated proteins might be clinical 
markers and predictors for poor survival in HCC. 
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4.2 Introduction 
Liver cancer – with its predominant form hepatocellular carcinoma (HCC) – 
represents the second most common cause of cancer-related death worldwide (Bruix 
et al., 2015; Tang et al., 2017). Although improvements in the survival of patients with 
HCC have been achieved in the past two decades, the prognosis of HCC remains 
one of the worst amongst all cancers (De Angelis et al., 2014; Tang et al., 2017). One 
major issue regarding the therapy of HCC is its chemoresistance: no effective 
conventional systemic chemotherapy for patients with advanced hepatocellular 
carcinoma has been established until now, resulting in poor prognosis of these 
patients (Yau et al., 2008). The response rate for sorafenib, the only approved drug 
besides regorafenib for systemic treatment in the late stage of the disease, is below 
3.5%, and a systemic combination of sorafenib and doxorubicin also leads to poor 
response rates up to a maximum of 6% (Wörns et al., 2009). Chemoresistance is 
closely linked to a poor prognosis, not only in HCC, but also in other cancer types 
(Cheng et al., 2016; Hamilton and Rath, 2014; Jiao and Nan, 2012). 
It is known that only 2% of the genome encodes for proteins, whereas the 
considerably larger part of the transcribed human genome consists of non-coding 
sequences (Consortium IHGS, 2004). One of these sequences is the long non-
coding RNA nuclear paraspeckle assembly transcript 1 (NEAT1). NEAT1 is located in 
nuclear paraspeckles (Mao et al., 2011), which are found in the nucleus’ 
interchromatin space (Clemson et al., 2009; Souquere et al., 2010). The two 
transcript variants of NEAT1 described in the literature are the short NEAT1_v1 
(NEAT1ε, 3.7 kb in length) and the long NEAT1_v2 (NEAT1-202, NEAT1β, 23 kb in 
length). Ensembl lists four additional transcript variants (NEAT1-201, 203 – 205) 
(Figure 1). Although NEAT1_v1 and NEAT1_v2 transcript variants are essential for 
the integrity of paraspeckles, the long transcript variant is more important for de novo 
paraspeckle assembly (Naganuma et al., 2012). The biological role of paraspeckles 
is widely unknown, not least due to the lack of an altered phenotype in Neat1 knock-
out mice (Nakagawa and Hirose, 2012). Recently, it has been suggested that NEAT1 
enhances chemoresistance in several cancer cells (Adriaens et al., 2016). Since data 
on NEAT1 in HCC chemosensitivity are completely lacking, we aimed to study 
NEAT1 expression as well as NEAT1-dependent paraspeckle formation in HCC and 
in chemoresistant compared to chemosensitive HCC cell lines.  
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Figure 1.  NEAT1 gene locus. Size and location of NEAT1 transcript variants on the NEAT1 gene 
locus on chromosome 11 (schematic). Coloured areas indicate regions amplified in the respective 
qPCR reaction. Please note that the scheme is not drawn in scale.  
 
With the recently described effect of increased HCC cell proliferation induced by 
NEAT1_v1/v2 in HCC cells (Fang et al., 2017; Liu et al., 2017), we also sought to 
determine whether its expression might serve as a prognostic clinical marker. 
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4.3 Materials & Methods 
4.3.1 TCGA data 
RNAseq expression data were obtained from The Cancer Genome Atlas pan cancer 
dataset produced via Toil (Vivian et al., 2017). RSEM (Li and Dewey, 2011) reported 
transcripts per million values were downloaded via the UCSC Xena Browser 
(https://xenabrowser.net) and comprised 369 primary solid tumour as well as 50 
matched non-tumour tissue samples for gene expression (see also Supplementary 
Table 1 for NEAT1 transcript variants). Only transcript variants with an average 
expression rate of log2(TPM + 0.001) > 0 were considered for analysis in the R 
statistical environment (v. 3.4.2). For survival analysis we considered two groups 
(split at 50% quantile) and three groups (split at 25% and 75% quantiles), 
respectively. Significance of differences between survival curves was computed with 
a log rank test using the survival R package. Further, we determined pairwise 
Pearson correlation of transcript expression and plotted them using the corrplot R 
package. These data were kindly compiled and analysed by Dr. Markus List and Dr. 
Marcel H. Schulz (Department of Computational Biology and Applied Algorithmics, 
Max Planck Institute for Informatics, Saarbrücken, Germany). 
 
4.3.2 Cell culture  
HepG2, PLC/PRF/5, and Huh7 cells were cultured in RPMI-1640 medium with 10% 
fetal calf serum, 1% penicillin/streptomycin and 1% glutamine (Sigma-Aldrich, 
Taufkirchen, Germany) at 37°C and 5% CO2. To induce and maintain 
chemoresistance, cells were regularly treated with either doxorubicin (Sigma-Aldrich) 
or sorafenib (Biomol, Hamburg, Germany) as previously described (Schultheiß et al., 
2017). Chemoresistance was regularly confirmed via IC50 determination by MTT 
assay. All cell lines were tested regularly for mycoplasma contamination and found 
negative. All cell lines were authenticated by the DSMZ (Braunschweig, Germany). 
The cells were cultured and treated in collaboration with Mrs Christina S. Hubig 
(Department of Pharmaceutical Biology, Saarland University, Saarbrücken, 
Germany). 
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4.3.3 RNA isolation and qPCR 
Total RNA was extracted using Qiazol lysis reagent (Qiagen, Hilden, Germany) 
according to the manufacturer’s protocol. Residual genomic DNA was removed by 
treatment with DNase I (Ambion / Invitrogen, Carlsbad, California, USA). Reverse 
transcription was performed using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, California, USA) as recommended by the supplier. 
Real-time quantitative polymerase chain reaction (qPCR) was performed in a CFX96 
cycler (Bio-Rad, München, Germany) with 5× HOT FIREPol® EvaGreen® qPCR Mix 
Plus (Solis BioDyne, Tartu, Estonia). All samples were estimated in triplicate. The 
following primers were used (see also Figure 1): NEAT1_v1/v2 forward: 
TGCTACAAGGTGGGGAAGACTG; NEAT1_v1/v2 reverse: 
CCCACACCCCAAACAAAACAA; NEAT1_v1/201/v2 forward: 
CCCCTTCTTCCTCCCTTTAAC; NEAT1_v1/201/v2 reverse: 
CCTCTCTTCCTCCACCATTAC; NEAT1_v2 forward: 
TTTCAAAGGGAGCAGCAAGGG; NEAT1_v2 reverse: 
ACGGCACAGGCAAATAAGACAC. Annealing temperature was 60°C for 
NEAT1_v1/v2 and NEAT1_v1/201/v2, and 64°C for NEAT1_v2. Primer 
concentrations for all three were 0.25 µM. Efficiency for each experiment was 
determined using a standard dilution series. Standards from 10 to 0.0001 amol of the 
PCR product cloned into the pGEM-T Easy vector (Promega, Madison, Wisconsin, 
USA), were run alongside the samples to generate a standard curve. The absolute 
gene expression was normalised to ACTB mRNA values. 
 
4.3.4 Immunofluorescence 
Cells were grown on coverslips overnight and fixed with 4% paraformaldehyde for 15 
min on ice. After permeabilisation with 1% Triton X 100 for 15 min, unspecific binding 
was blocked using a combination of 2% bovine serum albumin and 10% FCS for 1.5 
h. The cells were incubated with paraspeckle component 1 (PSPC1) antibody (1:20 
dilution; sc-374181, Santa Cruz, CA, USASA) overnight at 4°C. After washing, the 
secondary antibody, goat anti-mouse AlexaFluor 488 (Invitrogen, Karlsruhe, 
Germany), was added for 1.5 h at room temperature. After washing and adding DAPI 
(Sigma-Aldrich) for nuclear staining, coverslips were mounted with FluorSave™ 
(Calbiochem, Sandhausen, Germany). Images were obtained and analysed with an 
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Axio Observer Z1 epifluorescence microscope equipped with an AxioCam Mrm 
(Zeiss, Oberkochen, Germany). All cell images were obtained using either a 63x 
objective (for Huh7 and PLC/PRF/5 cells), or a 100x objective (for HepG2 cells). Data 
were obtained and analysed using the AxioVision software (Zeiss). 
 
4.3.5 Statistical analysis 
Data analysis and statistics were performed with OriginPro 8.6G (OriginLab 
Corporation, Northampton, USA). Values were expressed as box plots with 25th/75th 
percentile boxes, geometric medians (line), means (square), and 10th/90th percentile 
as whiskers. Statistical differences were calculated using an independent two-sample 
t-test or Mann-Whitney test as indicated depending on whether the data were 
normally distributed. 
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4.4 Results 
To determine a possible role of NEAT1 in HCC chemoresistance, we established 
human hepatoma cells (HepG2, PLC/PRF/5 and Huh7) resistant to the 
chemotherapeutics sorafenib or doxorubicin (Schultheiß et al., 2017) and checked 
NEAT1_v1/v2, NEAT1_v1/201/v2, and NEAT1_v2 expression in these cells. 
NEAT1_v1/v2 was significantly overexpressed in all three sorafenib and doxorubicin 
resistant cell lines (Figure 2A, B). In addition, sorafenib resistant HepG2 and Huh7 
cells as well as doxorubicin resistant PLC/PRF/5 and Huh7 cells showed an 
increased expression of NEAT1_v1/201/v2 and NEAT1_v2 (Figure 2A, B). 
 
Figure 2. NEAT1 expression in chemoresistant hepatoma cell lines. NEAT1_v1/v2, 
NEAT1_v1/v2/201, and NEAT1_v2 expression determined by qPCR in sorafenib resistant (A) and 
doxorubicin resistant (B) cells (n = 3, triplicates). Statistical difference: *: p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 
0.001. 
 
NEAT1_v2 was found to be important for de novo paraspeckle assembly (Naganuma 
et al., 2012). Due to overexpression of NEAT1_v2, we speculated that the 
chemoresistant hepatoma cell lines should have an increased paraspeckle formation. 
Therefore, cells were stained for the paraspeckle specific protein paraspeckle 
component 1 (PSPC1). As expected, positive signals were detected in all 
chemoresistant cells, whereas no signal could be detected in the control cells (Figure 
3). The most distinct paraspeckle staining was observed in Huh7 cells, which showed 
the highest NEAT1_v2 expression (Figure 2A, B). Our data suggest that doxorubicin 
resistance induces paraspeckle formation slightly more intensely compared to 
sorafenib resistance, which is in accordance with the higher NEAT1_v2 RNA 
expression in doxorubicin resistant PLC/PRF/5 and Huh7 cells (Figure 2B, 3). In 
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addition, doxorubicin resistant HepG2 cells tended to have fewer PSPC1-positive 
cells than sorafenib resistant HepG2 cells. PLC/PRF/5 and Huh7 cells showed no 
differences regarding this aspect (Figure 3).  
 
 
Figure 3. Paraspeckle formation in chemoresistant human hepatoma cells. Figure shows a 
representative image of doxorubicin and sorafenib resistant HepG2, PLC/PRF/5 and Huh7 cells. DAPI: 
blue, PSPC1: green.   
 
Our data show a distinct connection of chemoresistance, NEAT1 induction, and 
paraspeckle formation in three different HCC cell lines. Accordingly, two recently 
published papers described that NEAT1_v1/v2 knockdown resulted in elevated 
apoptosis and reduced viability / proliferation in different HCC cell lines (Fang et al. 
2017; Liu et al., 2017). Since our data indicate that chemosensitive cell lines do not 
form paraspeckles, one might speculate that NEAT1 might also act independently of 
paraspeckles. Since previous studies had reported elevated NEAT1 in HCC in 
samples from up to 95 patients (Guo et al., 2015; Wang et al., 2017), we 
hypothesised that NEAT1 expression might serve as a prognostic marker for HCC 
patients.  
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To test this hypothesis, we analysed the expression of total NEAT1 (including its 
transcript variants 201-205) as well as its single transcript variants (Figure 1) in the 
TCGA dataset comprising 369 HCC tissues and 50 non-tumour tissues. We could 
confirm that the expression of total NEAT1 was significantly increased in the tumour 
tissues as were the transcript variants NEAT1-201, NEAT1-202, and NEAT1-205, 
while the expression of NEAT1-203 and NEAT1-204 was below the threshold (Figure 
4A; Supplementary Table 2).  
 
Figure 4. NEAT1, PSPC1, NONO, and RBM14 expression in human liver tissue. Expression of 
total NEAT1 and its transcript variants (A) and the transcript variants of PSPC1 (B), NONO (C), and 
RBM14 (D) in human tumour and non-tumour tissue from a TCGA data set. The figure only shows the 
transcript variants with an average expression rate of log2(TPM + 0.001) > 0.  Statistical difference: **: 
p ≤ 0.01; ***: p ≤ 0.001. 
 
Interestingly, though, there was no significant correlation with survival for any of the 
differentially expressed NEAT1 transcripts (Table 1; Supplementary Figure 1). 
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gene transcript variant p-value 
≤ 50% vs > 50% quantile 
p-value 
> 25% & ≤ 75% vs ≤ 25% vs  
> 75% quantile 
NEAT1 201 0.1 0.25 
 202 0.53 0.19 
 205 0.88 0.25 
PSPC1 201 0.4 0.4 
 203 0.0022 0.0092 
 204 0.075 0.16 
 206 0.026 0.071 
NONO 201 0.055 0.099 
 202 0.00019 0.00072 
 210 0.065 0.18 
 211 0.022 0.068 
RBM14 201 0.0025 0.007 
 202 0.16 0.2 
 
Table 1. Survival analysis of NEAT1, PSPC1, NONO, and RBM14 expression levels. Results of 
survival / time ratio depending on the expression levels (comparing two or three groups) of the 
transcript variants of NEAT1, PSPC1, NONO, and RBM14 with an average expression rate of 
log2(TPM + 0.001) > 0. p-values ≤ 0.05 were considered as significant and are printed in bold letters. 
 
With NEAT1 representing a critical regulator and component of paraspeckles, we 
wondered whether the expression of genes encoding paraspeckle proteins was 
upregulated in HCC. For that, we analysed the expression of transcripts encoding 
PSPC1, non-POU domain containing octamer binding protein (NONO), and RNA-
binding motif protein 14 (RBM14) in the TCGA samples. All transcripts described in 
Ensembl release 91 (Zerbino et al., 2017) were analysed, whereby only transcripts 
reaching the threshold mean expression of log2(TPM + 0.001) > 0 were taken into 
consideration (Supplementary Table 2).  
We found that the expression of transcripts encoding for all three paraspeckle 
proteins was significantly elevated in HCC. For PSPC1, this was true for both protein 
coding transcripts 201 and 206 as well as for the non-coding transcripts 203 and 204 
(Figure 4B). Additionally, the expression of the protein coding NONO transcripts 201 
and 202 as well as the non-coding processed transcripts 210 and 211 were 
significantly elevated in HCC (Figure 4C). For RBM14, the two protein coding 
transcripts 201 and 202 were significantly elevated (Figure 4D). Most interestingly, 
there was a significant association with poor prognosis for transcripts encoding for all 
three paraspeckle proteins (Table 1; Supplementary Figure 2-4) 
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Except for RBM14-202, expression levels of all protein-coding and non-coding 
paraspeckle-associated transcripts showed distinct correlations with each other 
(Figure 5). 
 
Figure 5. Pairwise correlation of transcript variants with an average expression rate of 
log2(TPM + 0.001) > 0 of NEAT1, PSPC1, NONO, and RBM14. The lower triangle indicates 
correlation coefficients numerically, whereas the upper triangle depicts them as ellipsoids. Blue 
indicates positive and red negative correlation as reflected by the colour legend on the right-hand side.
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4.5 Discussion 
An implication of NEAT1 in the process of chemoresistance was previously described 
in human breast cancer MCF-7, neuroblastoma NGP, colon carcinoma HCT116, and 
osteosarcoma U2OS cells (Adriaens et al., 2016). Our study is the first to implicate 
NEAT1 in HCC chemoresistance. We found the variants NEAT1_v1 and NEAT1_v2 
to be significantly overexpressed in HepG2, PLC/PRF/5, and Huh7 cells that have 
developed resistance against either sorafenib or doxorubicin. 
Although it is known that NEAT1 plays an important role in paraspeckle formation 
(Naganuma et al., 2012), the complete function of paraspeckles is as yet unknown. 
However, it is assumed that they locate proteins inside the nucleus and are 
implicated in the reprogramming of a cell that takes place with differentiation. This 
may happen due to the inhibition of the expression of key proteins via nuclear RNA 
retention (Fox and Lamond, 2010). Paraspeckles were also reported to contribute to 
tumourigenesis by inhibiting DNA damage-induced cell death (Gao et al., 2014). 
Although paraspeckles have been described in diverse cell lines (Nakagawa and 
Hirose, 2012), to our knowledge, our report is the first one showing paraspeckles and 
their induction in liver cells. NEAT1_v2 – which constitutes paraspeckles – was 
elevated in nearly all of the analysed chemoresistant hepatoma cells. For cell lines 
showing induction of NEAT1_v2 but not of NEAT1_v2 and NEAT1_v1/201/v2 RNA, 
an elevated expression of NEAT1_v1 seems probable. However, this assumption 
cannot be confirmed definitely due to the lack of a unique sequence of NEAT1_v1 
(Figure 1). Although NEAT1_v1 cannot induce nuclear body formation by itself 
(Naganuma et al., 2012), it was suggested to increase the number of paraspeckles 
(Clemson et al., 2009). Another hypothesis is that NEAT1_v1 localises in non-
paraspeckle foci (so called 'microspeckles'), which may carry paraspeckle-
independent functions (Gao et al., 2014). Our findings indicate an elevated 
expression of NEAT1_v1 in doxorubicin resistant HepG2 cells compared to sorafenib 
resistant HepG2 cells. Since paraspeckles were also detected in doxorubicin 
resistant HepG2 cells, which showed no increased expression of NEAT1_v2, a 
positive association between NEAT1_v1 and the number of paraspeckles seems to 
be likely. These results are consistent with previous findings on a link between 
NEAT1_v1/v2 and NEAT1_v2 expression and chemoresistance in several other 
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tumour types (Adriaens et al., 2016) and extend them towards chemoresistance in 
HCC.  
Despite the effect of NEAT1 on chemoresistance, it was recently reported that 
knockdown of NEAT1_v1/v2 increased apoptosis and reduced both viability and 
proliferation in different HCC cell lines (Fang et al. 2017; Liu et al., 2017). Since we 
could not detect any paraspeckles in untreated, chemosensitive HCC cells, 
NEAT1_v1/v2 may also have additional, paraspeckle-independent functions related 
to cell viability.  
NEAT1 expression has been shown to be upregulated in different human 
malignancies, including lung cancer, colorectal cancer, prostate cancer, breast 
cancer, and HCC (Yu et al., 2017). However, the differentiation between the 
transcript variants of NEAT1 to our knowledge was never reported. We therefore 
decided to analyse the expression of the transcript variants of NEAT1 in human HCC 
tissue and were able to demonstrate that the transcript variants NEAT1-201, NEAT1-
202, and NEAT1-205 are elevated in HCC tissue in several hundred tumour samples 
compared to normal tissues. We were also able to confirm previous findings, in which 
an increased expression of NEAT1_v1/v2 for up to 95 HCC vs. non-cancerous liver 
tissues – as assessed by qPCR – was reported (Guo et al., 2015; Wang et al., 2017). 
Although NEAT1_v1/v2 has been reported to be associated with poor survival 
prognosis in breast cancer, oesophageal squamous cell carcinoma, and HCC (Chen 
et al., 2015; Choudhry et al., 2015; Liu et al., 2017), we could not confirm a significant 
association of the expression of NEAT1 transcripts with survival in HCC in this study.  
Although the elevated expression of NEAT1 transcripts suggests NEAT1 as a clinical 
marker for HCC, there is one major issue regarding this aspect: the stability of 
NEAT1. In fact, a study performing a genome-wide analysis of long non-coding RNA 
stability found Neat1 to be “one of the least stable lncRNAs” (Clark et al., 2012). 
Hence, expression analysis of NEAT1 in clinical practice may lead to incorrect 
results, while PSPC1 as a marker for NEAT1-dependent paraspeckle formation 
(Naganuma et al., 2012) may be a more valid marker for HCC prognosis.  
In addition to NEAT1, we also found transcripts of the paraspeckle-associated 
proteins PSPC1, NONO, and RBM14 to be upregulated in HCC compared to non-
cancerous liver tissue. PSPC1 has not only been shown to be upregulated in 
colorectal carcinoma (Albrethsen et al., 2010), but is also involved in the acquisition 
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of chemoresistance in HeLa cells (Gao et al., 2014). Another paraspeckle related 
protein, NONO, was reported to promote tumour growth in breast cancer (Zhu et al., 
2016) and to be associated with chemoresistance in colorectal carcinoma cells 
(Tsofack et al., 2011). The expression of RBM14 is upregulated in non-small cell lung 
carcinoma, lymphoma, pancreatic cancer and ovarian cancer (Sui et al., 2007). In 
addition, RBM14 contributes to glioblastoma multiforme resistance (Kai 2016). Due to 
the as yet not reported upregulation of several transcripts of PSPC1, NONO, and 
RBM14 in HCC compared to non-tumour tissue, we suggest them also as markers 
for HCC. Since at least one transcript of each of these proteins was associated with 
poor survival prognosis in HCC, they may also serve as prognostic markers in HCC. 
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4.6 Conclusion 
In conclusion, a detailed functional analysis of paraspeckle function in HCC might 
reveal NEAT1 and paraspeckle-related proteins as promising targets for the 
development of novel HCC therapies, and PSPC1, NONO, and RBM14 as clinical 
prognostic markers for HCC. 
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4.7 Supplementary data 
Supplementary Figure 1. Kaplan-Meier curves of NEAT1 transcript variants with an average 
expression rate of log2(TPM + 0.001) > 0. 
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Supplementary Figure 2. Kaplan-Meier curves of PSPC1 transcript variants with an average 
expression rate of log2(TPM + 0.001) > 0 . 
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Supplementary Figure 3. Kaplan-Meier curves of NONO transcript variants with an average 
expression rate of log2(TPM + 0.001) > 0. 
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Supplementary Figure 4. Kaplan-Meier curves of RBM14 transcript variants with an average 
expression rate of log2(TPM + 0.001) > 0. 
 
 
transcript NCBI Reference Sequence Ensembl Transcript ID 
NEAT1_v1 NR_028272.1 - 
NEAT1_v2 / NEAT1-202 NR_131012.1 ENST00000501122.2 
NEAT1-201 - ENST00000499732.2 
NEAT1-203 - ENST00000601801.2 
NEAT1-204 - ENST00000612303.1 
NEAT1-205 - ENST00000616315.1 
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biotype mean expression 
above threshold of 
log2(TPM + 0.001) > 0 
NEAT1 201 ENST00000499732 lincRNA yes 
 202 ENST00000501122 lincRNA yes 
 203 ENST00000601801 lincRNA no 
 204 ENST00000612303 lincRNA no 
 205 ENST00000616315 lincRNA yes 
PSPC1 201 ENST00000338910 protein coding yes 
 202 ENST00000427943 protein coding no 
 203 ENST00000471658 nonsense mediated decay yes 
 204 ENST00000492741 nonsense mediated decay yes 
 205 ENST00000497722 retained intron no 
 206 ENST00000619300 protein coding yes 
 207 ENST00000635251 retained intron no 
 208 ENST00000635562 nonsense mediated decay no 
NONO 201 ENST00000276079 protein coding yes 
 202 ENST00000373841 protein coding yes 
 203 ENST00000373856 protein coding no 
 204 ENST00000413858 protein coding no 
 205 ENST00000418921 protein coding no 
 206 ENST00000420903 protein coding no 
 207 ENST00000450092 protein coding no 
 208 ENST00000454976 protein coding no 
 209 ENST00000471419 processed transcript no 
 210 ENST00000472185 processed transcript yes 
 211 ENST00000473525 processed transcript yes 
 212 ENST00000474431 processed transcript no 
 213 ENST00000486613 processed transcript no 
 214 ENST00000490044 processed transcript no 
 215 ENST00000535149 protein coding no 
RBM14 201 ENST00000310137 protein coding yes 
 202 ENST00000393979 protein coding yes 
 203 ENST00000409372 protein coding no 
 204 ENST00000409738 protein coding no 
 205 ENST00000443702 protein coding no 
 206 ENST00000460762 processed transcript no 
 207 ENST00000461478 processed transcript no 
 208 ENST00000496694 processed transcript no 
 209 ENST00000512283 processed transcript no 
 
Supplementary table 2. Function and mean expression threshold of all transcript variants of 







Primary liver cancers including hepatocellular carcinoma (HCC) are the second most 
common cause of cancer related death worldwide. The incidence of HCC is specially 
rising in most industrialised countries, although HCC is still prevalent in Asian and 
African countries. An increased incidence of HCC can be observed in patients 
suffering from metabolic disorders.  
Short-term diethylnitrosamine (DEN) treatment reduced both body and liver weight 
and drove severe liver injury and acute hepatic inflammation. Moreover, DEN 
strongly altered immune cell and hepatic lipid composition. Hence, it may be a 
powerful model to analyse the role of tumour supressors / promoters regarding the 
hepatic pathomechanisms related to immune cell and lipid composition in a tumour-
promoting environment.   
Hepatic TTP expression was strongly decreased in HCC tissues in three publicy 
available data sets compared to non-tumour samples. In addition, TTP expression 
was decreased in tumour but not in cirrhotic tissue, which may qualify TTP as a 
useful marker for the progression from the cirrhotic state towards HCC. Although TTP 
was decreased in HCC patients, hepatocyte Ttp knockout animals showed a lower 
number of tumours and less inflammation compared to the wild-type animals. 
However, TTP negatively regulated several tumour-promoting factors. The 
chemosensitising role of TTP in HCC could be shown by the decreased viability of 
TTP-overexpressing hepatoma cells, especially of Huh7 cells, after doxorubicin or 
sorafenib treatment. In addition, overexpression of TTP inhibited the migration ability 
of Huh7 and PLC/PRF/5 cells. The most distinct effect was shown in the strongly 
decreased proliferation in HepG2, Huh7 and PLC/PRF/5 cells, which overexpressed 
TTP. TTP-overexpressing hepatoma cells also showed a downregulation of several 
oncogenes, e.g. BCL2, MYC, and VEGFA. DNA hypomethylation increased TTP 
expression in HepG2 and Huh7 cells. However, the analysis of TTP promoter 
methylation in human liver tissue showed no difference between normal and tumour 
tissue. Therefore, TTP promotes hepatic tumour initiation but inhibits hepatic tumour 
progression.   
An impact of NEAT1-dependent paraspeckle formation on the process of 
chemoresistance in HCC was supported by the highly abundant presence of NEAT1 
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variants in either sorafenib or doxorubicin resistant accompanied by the induction of 
paraspeckles. In addition, the overexpression of several NEAT1 transcripts and of 
transcripts of the paraspeckle-associated proteins PSPC1, NONO, and RBM14 in 
HCC confirmed the clinical relevance of these results. Morover, some of these 
transcripts correlated with poor survival in HCC. Therefore, these genes may not only 







The following figures show results obtained within this thesis from gene expression 
analysis by qPCR and from protein analysis by flow cytometry or Western Blot. They 
either revealed non-statistically significant effects or are related to other projects. This 
is why they will not be discussed in detail. 
 
Supplementary Fig 1. Effects of DEN on hepatic expression of genes involved in inflammation. 
Expression of Mcp1 (encodes chemokine (C-C motif) ligand 2 (Ccl2)), Ccl7 (encodes chemokine (C-C 
motif) ligand 7 (Ccl7)), Cxcl10 (encodes C-X-C motif chemokine 10 (Cxcl10)), Tnf (encodes tumor 
necrosis factor alpha (Tnf-a), Il1b (encodes interleukin 1 beta (Il1β), Il6 (encodes Interleukin 6 (Il-6)), 
Tsc22d3 (encodes glucocorticoid-induced leucine zipper (Gilz), Adgre1 (encodes F4/80), Ccr2 
(encodes C-C chemokine receptor type 2 (Ccr2)), Flt3 (encodes CD135), Zfp36 (encodes 












Supplementary Fig 2. Effects of hypomethylation on HuR expression in hepatoma cells. HuR 
mRNA expression levels in HepG2, PLC/PRF/5, and Huh7 cells treated with decitabine. n ≥ 2, 





























Supplementary Fig 3. Kinase signaling in TTP-overexpressing hepatoma cells.  Cells were 
transfected with either a TTP sense construct or an antisense construct as a control. 48h after 
infection, protein lysates of the cells were separated via sodium dodecyl sulfate and analysed via 
Western Blot as described previously (Kessler et al., 2013). The following antibodies were used for 
detection: p44/42 (Erk1/2) (L34F12) antibody (#4696S, New England Biolabs, Ipswich, 
Massachusetts, USA), phospho-p44/42 MAPK (T202/Y204) 20G11 antibody (#4376S, New England 
Biolabs), Akt antibody (#9272S, New England Biolabs), phospho-Akt (Ser473) (D9E) XP® antibody 
(#4060, New England Biolabs), PTEN antibody (#9552, New England Biolabs), p38 MAPK antibody 
(sc-7972, Santa Cruz), and phospho-p38 MAPK antibody (#9215S, New England Biolabs). 
Densitometric analysis of Western blots from HepG2 (A), Plc/prf/5 (B), and Huh7 (C). Data are 
expressed as ratio of p44/42, Akt, PTEN, or p38 MAPK to tubulin signal intensities or as ratio of 
phosphorylated p44/42 (p-p44/42), Akt (p-Akt), or p38 MAPK (p-p38) to total p44/p42, Akt, or p38 
MAPK signal intensities. n = 3, duplicates. Statistical difference: *: p ≤ 0.05. 
Kommentar [A1]: Blots etc. schaffe ich 











Supplementary Fig 4. NEAT1 expression in human tumour and non-tumour liver tissue. 
NEAT1_v1/v2 and NEAT1_v2 mRNA levels isolated of tumour and adjacent non-tumour tissues (n = 
31) as described in chapter 3 by qPCR normalised to ACTB. 
 
Supplementary Fig 5. PSPC1 expression in chemoresistant hepatoma cell lines. PSPC1 
expression determined by qPCR in doxorubicin resistant (A) and sorafenib resistant (B) cells (n = 3). 
Primers detected transcript variants PSPC1_v1 (NM_001042414.3), PSPC1_v4 (NM_001354909.1), 
and PSPC1_v6 (NR_149052.1), which are listed on the NCBI database. The primers also detect 
PSPC1-201 (ENST00000338910.8) and PSPC1-206 (ENST00000619300.4), which are listed on 
Ensembl. The following primer sequences were used: PSPC1 forward: 
AGACGCTTGGAAGAACTCAGA, PSPC1 reverse: TTGGAGGAGGACCTTGGTTAC. Statistical 








Supplementary Fig 6: Effect of H19 on proliferation and inflammation. (A) Flow cytometric 
analysis of the proliferation marker MKI67 in stably H19-overexpressing (H19) and vector control 
human hepatoma cells (control), n ≥ 2, triplicates. (B) Expression of H19 mRNA levels in short-term 
DEN-treated wild-type mice, n = 6. Experiments were conducted as described previously (Schultheiß 
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